

Michael A. Horberg, MD, MAS, FACP, FIDSA

Associate Medical Director

Areas of Responsibility: Research, Medical Education, Community Health, Medicaid, Genetics,
HIV & STD, Transgender Health, Infection Prevention and Control

Mid-Atlantic Permanente Medical Group PC

2101 East Jefferson Street

Rockville, MD 20852

Phone: 301-816-6302

michael.horberg@kp.org

VERBAL INTRODUCTION

Michael Alan Horberg, MD, MAS, FACP, FIDSA is Associate Medical Director for Kaiser Permanente Mid-Atlantic Permanente Medical Group (MAPMG). In that role, he has responsibilities for Research, Medical Education, Community Health, Medicaid, Genetics, HIV and STD, Transgender Health and Infection Control and Prevention. He serves as the Executive Director of the Mid-Atlantic Permanente Research Institute (MAPRI). As Executive Director, Dr. Horberg is responsible for all research activities in Kaiser Permanente Mid-Atlantic States (KPMAS). As Associate Medical Director for Medical Education, he is the Designated Institutional Official for KPMAS.

Dr. Horberg serves as the medical director for KPMAS Community Health, and is the Medicaid leader for MAPMG, including Chief Medical Officer for KPMAS in Maryland Medicaid, as well as helping lead clinical operational efforts in both Maryland and Virginia Medicaid, and serving on the KPMAS Medicaid Executive Committee. Michael leads HIV, STD, Infection Prevention, and transgender health care efforts in the KPMAS region, and HIV and STD care program-wide for Kaiser Permanente. This year, he is leading the opening of *Pride Medical* and KPMAS' *Gender Pathways* programs and clinics within KPMAS. Dr. Horberg leads the Medical Genetics and Genomics strategy for MAPMG and is Executive Sponsor for KPMAS' Commission on Cancer Accreditation and National Surgical Quality Improvement Program.

Dr. Horberg serves as director of HIV/AIDS program-wide for Kaiser Permanente and as Clinical Lead for HIV/AIDS and STDs for the Care Management Institute. Under President Obama, Dr. Horberg has served on the Presidential Advisory Council on HIV/AIDS, having co-chaired the Access to Care and Improved Outcomes Committee. Dr. Horberg is a Fellow of the American College of Physicians and the Infectious Disease Society of America (IDSA). He is Past-Chair of the Board of Directors of the HIV Medicine Association of IDSA. He has served on the IDSA Quality Performance Committee, and presently co-chairs the IDSA Primary Care Guideline Committee. Dr. Horberg has served as a commissioner on the State of Maryland Natalie M. LaPrade Medical Cannabis Commission. He is past-president of the national Gay and Lesbian Medical Association.

In his role as Executive Director of MAPRI, Dr. Horberg leads a department of both clinical and data research with over sixty team members. His HIV research interests are health service outcomes for HIV-infected patients (including HIV quality measures and care improvement, and determinants of optimized multidisciplinary care for maximized HIV outcomes), medication adherence issues in these patients, and epidemiology of the disease. Dr. Horberg serves as the MAPRI and national principal investigator for the Kaiser Permanente Research Bank (national genomics initiative). Other research interests include other sexually transmitted diseases and hepatitis. Dr. Horberg has published over 150 manuscripts and delivered over one hundred presentations at scientific meetings; all are in peer-reviewed literature or conferences. He has chaired multiple Expert Panels on HIV-related provider performance measures (including ones sponsored by CMS, NCQA, and IDSA), and has served on NIH and CDC peer-review panels.

A Chicagoan by birth, Dr. Horberg attended Boston University Medical School, and received his Master of Advanced Studies, from University of California San Francisco. He is a resident of the District of Columbia with his husband Chip and their pet poodle Grant.

EDUCATION AND TRAINING

University of California San Francisco, San Francisco, CA
M.A.S. (Master of Advanced Study in Clinical Research) 2004-2006

University of Chicago/Michael Reese Hospital, Chicago, IL
Residency, Categorical Internal Medicine 1985-1988

Boston University School of Medicine, Boston, MA
M.D. 1981-1985

Boston University, Boston, MA
B.A. in Medical Science with Minor in History 1979-1985
Summa cum Laude, Phi Beta Kappa

APPOINTMENTS AND EMPLOYMENT

Mid-Atlantic Permanente Medical Group, Rockville, MD 2011-
Mid-Atlantic Permanente Research Institute
Associate Medical Director Research, Medical Education, Community Health, Medicaid, Genetics, HIV and STD, Transgender Health, Infection Prevention
Executive Director, Mid-Atlantic Permanente Research Institute

Kaiser Permanente and The Permanente Federation, Oakland, CA
Care Management Institute
Director, HIV/AIDS and STDs 2003-

Kaiser Permanente Institute for Health Policy, Oakland, CA
Fellow 2010-

The Permanente Medical Group, Inc., Oakland, CA 1997-2011
Kaiser Permanente Northern California Division of Research
Chair, Central Research Committee
Research Scientist II
Senior Physician and Research Chair, Santa Clara Medical Center

Private Medical Practice, Chicago, IL 1988-1997

GOVERNMENT SERVICE/ APPOINTMENTS

Presidential Advisory Council on HIV/AIDS (PACHA)
Presidential Appointment /Special Government Employee 2010-2014
Co-chair, Access to Care and Quality Outcomes Committee 2010-2014

State of Maryland Natalie M. LaPrade Medical Cannabis Commission
Member, Commission 2013-2017

CDC Coalition on Sexual Health
Chair, Health Care Action Group 2012-

Patient-Centered Outcomes Research Institute (PCORI)
Member, PCORnet Engagement Council 2016-2018

<i>Institute for Public Health Innovation</i>	
Chair, Board of Directors	2018-2020
Member, Board of Directors	2013-
Member-at-Large, Executive Committee	2013-2018

<i>University of California Office of the President HIV/AIDS Research Program</i>	
Member, Advisory Council	2009-2011

<i>Visioning Change: State Office of AIDS and University of California HIV Research Program</i>	
Member, Leadership Committee	2009-2010

ACADEMIC APPOINTMENTS

<i>Bernard J. Tyson Kaiser Permanente School of Medicine</i>	
Professor	2018-

<i>Stanford University Medical School, Palo Alto, CA</i>	
Clinical Assistant Professor (Affiliated) of Medicine (Infectious Diseases)	2010-2012
Clinical Instructor	1998-2010

<i>Northwestern University Medical School, Chicago, IL</i>	
Clinical Instructor	1988-1996

<i>University of Illinois College of Medicine, Chicago, IL</i>	
Assistant Clinical Professor	1990-1996

BOARD CERTIFICATIONS AND LICENSURE

American Board of Internal Medicine	1989-
HIV Specialist Credentials—American Academy of HIV Medicine	2002-
California Medical License (Active)	1996-
District of Columbia Medical License (Active)	2011-
Illinois Medical License (Inactive)	1985-1996
Maryland Medical License (Active)	2011-
Commonwealth of Virginia Medical License (Active)	2011-

PROFESSIONAL AFFILIATIONS AND SERVICE

HIV Medicine Association (HIVMA) of the Infectious Disease Society of America	
Chair, Board of Directors	2012-2013
Chair, HIV MOC Committee	2009-2012
Board Member	2007-2014
Infectious Disease Society of America (IDSA)	
Fellow	2011-
Member, IDSA Education Committee	2009-2012
Member, IDSA Research Committee	2012-2014
Member, IDSA Quality Measures Committee	2014-
Chair, HIV Primary Care Guidelines Committee	2016-
American College of Physicians	
Fellow	1997-
Forum for Collaborative HIV Research	
Member, Executive Committee	2006-
Health Care Systems Research Network (formerly HMO Research Network)	
Board of Governors	2011-
Executive Committee	2018-

Gay and Lesbian Medical Association (GLMA, 2000 + members nationally) President	1997-1998
Gay and Lesbian Physicians of Chicago President	1994-1996
International AIDS Society Academy Health	2002- 2013-
International Association of Physicians in AIDS Care	2008-
American Academy of HIV Medicine (AAHIVM)	2000-2015
California Medical Association	1998-2011
AIDS Community Research Consortium	1997-2010
Bay Area Association of Physicians for Human Rights	1997-2011

SCIENTIFIC REVIEW PANEL ACTIVITIES

National Institutes of Health

Clinical Trial Units for NIAID Networks ZAI1-RB-A-S2	2013
Innovative Research in HIV in Kidney, Urology, and Hematology ZRG1 AARR M54	2016

Centers for Disease Control and Prevention

HIV Testing Program Sites	2010
---------------------------	------

KAISER PERMANENTE SERVICE (SELECTED APPOINTMENTS)

Kaiser Permanente Interregional

Director, HIV Interregional Initiative Steering Committee	2003-
Clinical Lead, KP HIV Clinical Care Guidelines	1998-
HIV, Hepatitis, and STI National Conference Conference Chair and Director	2004-
Interregional New Technologies Committee	2013-
National Research Committee Chair	2011- 2018-2020

Kaiser Permanente Northern California Region

Chair, Regional HIV Therapeutics Subcommittee	1998-2011
Health Services Institutional Review Board	2005-2011
Santa Clara Infection Control Committee	1997-2011

EDITORIAL ACTIVITIES

Editorial Board

<i>HIV and Behavior</i>	2019-
<i>The American Journal of Managed Care Evidence-Based Immunology and Infectious Disease</i>	
<i>Annals of the Forum for Collaborative HIV Research</i>	

Reviewer for the Following Journals:

AIDS and Behavior
AIDS, Patient Care, and STDs
AIDS Research and Human Retroviruses
American Journal of Kidney Diseases
Annals of Internal Medicine
Archives of Psychiatry
BMC Infectious Diseases
BMC Medical Informatics and Decision Making
BMC Medicine
HIV Clinical Trials
International Journal of Environmental Research and Public Health

JAIDS
Journal of Antimicrobial Chemotherapy
Journal of Infection
Pediatrics
The Permanente Journal)

Reviewer/Assistant Editor for the following Texts:
LGBTQ America Today: An Encyclopedia

Reviewer for the following Conferences:
Infectious Disease Society of America Annual Meeting
International AIDS Society International AIDS Conference
National Summit on HIV Diagnosis, Prevention, and Access to Care

MENTORSHIP AND TEACHING

Kaiser Permanente Northern California:
David Vinson, MD (Emergency Medicine; CREST Network)
Minggui Pan, MD (Oncology; Community Benefits Clinician Research)
Resident research at Kaiser Permanente Santa Clara Medical Center

Kaiser Permanente Mid-Atlantic States:
Sherri Johnson, RN (Doctoral research)
Jared Maeda, PhD (Health Services research scientist)
Chu-Ling Yu, ScD (Oncology Epidemiology research scientist)
Christine Bredfeldt, PhD (Health Informatics research scientist)

Kaiser Permanente Santa Clara Medical Center

Director and Preceptor, HIV Clinic for residents	1999-2010
Primary Care Preceptor in Clinic	1997-2010
Morning Report Attending (twice a month)	1997-2005
Ward Attending in Medicine	1998-2000

SPECIAL RECOGNITIONS

Washington Business Journal Business of Pride	2020
Mid-Atlantic Permanente Medical Group Excellence in Research Award	2016
City of Oakland, California, Mayor's Proclamation "Michael Horberg Day"	2010
Kaiser Permanente Santa Clara Teacher of the Year	2001, 2002

PUBLICATIONS AND ABSTRACTS

Peer-Reviewed Publications

1. Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, **Horberg M**, Flamm J, Follansbee S, Schapiro JM, Shafer RW. HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. *J Infect Dis.* 2005 Aug 1;192(3):456-65.
2. DeLorenze GN, Follansbee SF, Nguyen DP, Klein DB, **Horberg M**, Quesenberry CP Jr, Blick NT, Tsai AL. Medication error in the care of HIV/AIDS patients: electronic surveillance, confirmation, and adverse events. *Med Care.* 2005 Sep;43(9 Suppl):III63-8.
3. **Horberg M**, Antoniskis D, Bersoff-Matcha S, Hurley L, Klein D, Kovach D, Mogyoros M, Towner W, Weinberg W. Perceptions of human immunodeficiency virus testing services among HIV-positive persons not in medical care. *Sex Transm Dis.* 2006 Jul;33(7):464; author reply 465.

4. Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Slome S, Flamm J, **Horberg M**, Hurley L, Klein D, Shafer RW. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/mL," *J Acquir Immune Defic Syndr*. 2006 Sep;43(1):56-9.
5. **Horberg M**, Hurley LB, Klein DB, Follansbee SE, Quesenberry C, Flamm JA, Green GM, Luu T. Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. *Arch Surg*. 2006 Dec;141(12):1238-45.
6. Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, **Horberg M**, Schiffer CA, Zolopa AR, Shafer RW. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. *AIDS Res Hum Retroviruses*. 2006 Dec;22(12):1300-5.
7. Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, Calzavara L, Deeks SG, Eron JJ, Gebo KA, Gill MJ, Haas DW, Hogg RS, **Horberg M**, Jacobson LP, Justice AC, Kirk GD, Klein MB, Martin JN, McKaig RG, Rodriguez B, Rourke SB, Sterling TR, Freeman AM, Moore RD. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). *Int J Epidemiol*. 2007 Apr;36(2):294-301. Epub 2007 Jan 8.
8. **Horberg M**, Hurley LB, Silverberg MJ, Kinsman CJ, Quesenberry CP. Effect of clinical pharmacists on utilization of and clinical response to antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2007 Apr 15;44(5):531-9.
9. Silverberg MJ, Leyden W, **Horberg M**, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. *Arch Intern Med*. 2007 Apr 9;167(7):684-91.
10. Cheever LW, Lubinski C, **Horberg M**, Steinberg JL. Ensuring access to treatment for HIV infection. *Clin Infect Dis*. 2007 Dec 15;45 Suppl 4:S266-74.
11. **Horberg MA**, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, Weinberg WG, Antoniskis D, Mogyoros M, Dodge WT, Dobrinich R, Quesenberry CP, Kovach DA. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. *J Acquir Immune Defic Syndr*. 2008 Mar 1;47(3):384-90.
12. **Horberg M**, Silverberg M, Hurley L, Delorenze G, Quesenberry C. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. *AIDS Patient Care STDS*. 2008 Apr;22(4):301-12.
13. **Horberg M**, Klein D, Hurley L, Silverberg M, Towner W, Antoniskis D, Kovach D, Mogyoros M, Blake W, Dobrinich R, Dodge W. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients. *HIV Clin Trials*. 2008 Nov-Dec;9(6):367-74.
14. Silverberg MJ, Leyden W, Hurley L, Go AS, Quesenberry CP Jr, Klein D, **Horberg MA**. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. *Ann Intern Med*. 2009 Mar 3;150(5):301-13.
15. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, **Horberg M**, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA, Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. *N Engl J Med*. 2009 Apr 30;360(18):1815-26. Epub 2009 Apr 1.

16. Towner W, Klein D, Kerrigan HL, Follansbee S, Yu K, **Horberg M**. Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study. *J Acquir Immune Defic Syndr*. 2009 Aug 1;51(4):367-73.
17. Rhee SY, Fessel WJ, Liu TF, Marlowe NM, Rowland CM, Rode RA, Vandamme AM, Van Laethem K, Brun-Vezinet F, Calvez V, Taylor J, Hurley L, **Horberg M**, Shafer RW. Predictive value of HIV-1 genotypic resistance test interpretation algorithms. *J Infect Dis*. 2009 Aug 1;200(3):453-63.
18. Silverberg MJ, Leyden W, Quesenberry CP Jr, **Horberg M**. Race/Ethnicity and risk of AIDS and death among HIV-infected patients with access to care. *J Gen Intern Med*. 2009 Sep;24(9):1065-72.
19. Klein DB, Hurley LB, **Horberg M**, Silverberg MJ, Follansbee SE, Flamm JA, Green GM. Increased rates of appendicitis in HIV-infected men: 1991-2005. *J Acquir Immune Defic Syndr*. 2009 Sep 1;52(1):139-40.
20. **Horberg M**, Ranatunga DK, Quesenberry CP, Klein DB, Silverberg MJ. Syphilis epidemiology and clinical outcomes in HIV-infected and HIV-uninfected patients in Kaiser Permanente Northern California. *Sex Transm Dis*. 2010; 37(1): 53-58.
21. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, **Horberg M**, Klein D, Quesenberry CP Jr, Towner WJ, Abrams DI. HIV infection and the risk of cancers with and without a known infectious cause. *AIDS*. 2009 Nov 13;23(17):2337-45.
22. Deeks SG, Gange SJ, Kitahata MM, Saag MS, Justice AC, Hogg RS, Eron JJ, Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Benson CA, Collier AC, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk GD, Napravnik S, Rachlis AR, Calzavara LM, **Horberg M**, Silverberg MJ, Gebo KA, Kuschel MB, Goedert JJ, McKaig RG, Moore RD. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. *Clinical Infectious Diseases*, 2009;49(10):1582-90.
23. **Horberg M**, Tang B, Towner W, Silverberg M, Bersoff-Matcha S, Hurley L, Chang J, Blank J, Quesenberry C Jr, Klein D. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. *J Acquir Immune Defic Syndr*. 2010 Jan 1;53(1):62-9.
24. Mosen, D, **Horberg M**, Roblin D, Gullion, C, Meenan, R, Leyden, W, Hu, W. Effect of Once-daily FDC Treatment Era on Initiation of cART. *HIV/AIDS-Research and Palliative Care*, 2010 (2): 19-26.
25. Althoff K, Gange S, Klein M, **Horberg M**, Bosch R, Hogg R, Zhang J, Moore R on behalf of NA-ACCORD, "Late Presentation for HIV Care in the United States and Canada," *Clinical Infectious Diseases*, 2010 50(11):1512-1520.
26. Chao C, Xu L, Abrams D, Leyden W, **Horberg M**, Towner W, Klein D, Tang B, Silverberg M, "Survival of Non-Hodgkin Lymphoma Patients with and without HIV-Infection in the Era of Combined Antiretroviral Therapy," *AIDS*, 2010 Jul 17;24(11):1765-70
27. **Horberg M**, Aberg J, Cheever L, Renner P, Kaluba E, Asch S, "National and Multi-Agency HIV Quality Measures Development," *Clinical Infectious Diseases*, 2010; 51:732-738.
28. **Horberg M**, Klein, D, "An update on the use of Atripla in the Treatment of HIV in the US," *HIV—Research and Palliative Care*, 2010 (2): 135–140.
29. Althoff K, Gebo K, Gange S, Klein M, Brooks J, Hogg R, Bosch R, **Horberg M**, Saag M, Kitahata M, Eron J, Napravnik S, Rourke S, Gill MJ, Rodriguez B, Sterling T, Deeks S, Martin J, Jacobson L, Kirk G, Collier A, Benson C, Silverberg M, Goedert J, McKaig R, Buchacz K, Thorne J, Rachlis A, Moore R, Justice A, for the North American AIDS Cohort Collaboration on Research and Design, "CD4 count at

presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation?," *AIDS Research and Therapy*, 2010; 7:45.

30. **Horberg M**, Hurley L, Towner W, Gambatese R, Klein D, Antoniskis D, Weinberg W, Kadlecik P, Remmers C, Dobrinich R, Quesenberry C, Silverberg M, Johnson M, "HIV Quality Performance Measures in a Large Integrated Healthcare System," *AIDS, Patient Care, and STDs*, 2011; 25(1): 21-28.
31. Breyer B, van den Eeden S, **Horberg M**, Eisenberg M, Deng D, Smith J, Shindel A, "HIV Status is an Independent Risk Factor for Reporting Lower Urinary Tract Symptoms," *Journal of Urology*, 2011; 185(5):1710-5
32. Shindel A, **Horberg M**, Smith J, Breyer B, "Sexual Dysfunction, HIV, and AIDS in Men Who Have Sex with Men," *AIDS, Patient Care, and STDs*, 2011; e-pub ahead of print
33. Chao C, Xu L, Abrams D, Towner W, **Horberg M**, Leyden W, Silverberg M, "HMG-CoA Reductase Inhibitors (Statins) Use and Risk of Non-Hodgkin Lymphoma in HIV+ Persons," *AIDS*, 2011; 25: 1771-1777.
34. Potter M, Somkin C, Ackerson L, Gomez V, Dao T, **Horberg M**, Walsh J, "The FLU-FIT Program at Kaiser Permanente: An effective approach to increase colorectal cancer screening rates," *American Journal of Managed Care*, 2011; 17(8): 577-583
35. Abraham A, Lau B, Deeks S, Moore R, Zhang J, Eron J, Harrigan R, Gill MJ, Kitahata M, Klein M, Napravnik S, Rachalis A, Rodriguez B, Rourke S, Benson C, Bosch R, Collier A, Gebo K, Goedert J, Hogg R, **Horberg M**, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, "Missing Data in the Estimation of the Prevalence of Accumulated HIV Drug Resistance in Antiretroviral-Treated Patients in North America," *American Journal of Epidemiology*, 2011; 174(6): 727-735.
36. Sterling T, Lau B, Zhang J, Freeman A, Bosch R, Brooks J, Deeks S, French A, Gange S, Gebo K, Gill MJ, **Horberg M**, Jacobson L, Kirk G, Kitahata M, Klein M, Martin J, Rodriguez B, Silverberg M, Willig J, Eron J, Goedert J, Hogg R, Justice A, McKaig R, Napravnik S, Thorne J, Moore R, for NA-ACCORD of IeDEA, "Risk Factors for Tuberculosis After Highly Active Antiretroviral Therapy Initiation in the United States and Canada: Implications for Tuberculosis Screening Strategies," *Journal of Infectious Diseases*, 2011 Sep;204(6):893-901
37. Gallant J, Adimora A, Carmichael JK, **Horberg M**, Kitahata M, Quinlivan EB, Raper J, Selwyn P, Williams S, "Essential Components of Effective HIV Care: A Policy Paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Providers Coalition," *Clinical Infectious Diseases*, 2011; 53(11):1043-50
38. Silverberg M, Chao C, Leyden W, Xu L, **Horberg M**, Klein D, Towner W, Dubrow R, Quesenberry C, Neugebauer R, Abrams D, "HIV Infection, Immunodeficiency, Viral Replication, and the Risk of Cancer," *Cancer Epidemiology and Biomarkers Prevention*, 2011 Dec;20(12):2551-9
39. Schwarz EB, Postlethwaite D, Hung Y-Y, Lantzman E, Armstrong MA, **Horberg M**, "Provision of Contraceptive Services to Women with Diabetes," *Journal of General Internal Medicine*, 2012 Feb;27(2):196-201
40. Towner W, Xu L, Leyden W, **Horberg M**, Chao C, Tang B, Klein D, Hurley L, Quesenberry C, Silverberg M, "The Effect of HIV Infection, Immunodeficiency and Antiretroviral Therapy on the Risk of Hepatic Dysfunction," *JAIDS*, 2012 Jul 1;60(3):321-7

41. Chao C, Tang B, Towner W, Silverberg M, Hurley L, **Horberg M**, Short Term Clinical Outcomes among Treatment Experienced HIV+ Patients with Early Low Level Viremia," *AIDS Patient Care and STDs*, 2012 May;26(5):253-5
42. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, "Determination of Optimized Multidisciplinary Care Team for Maximal Antiretroviral Therapy Adherence," *JAIDS*, 2012 Jun 1;60(2):183-90
43. Chao C, Tang B, Hurley L, Silverberg M, Towner, W Preciado M, **Horberg M**, "Risk Factors for Short-Term Virologic Outcomes among HIV-Infected Patients undergoing Regimen Switch of Combination Antiretroviral Therapy," *AIDS Research and Human Retroviruses*, 2012; Dec;28(12):1630-6.
44. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, "Impact of Provider Experience Characteristics on Antiretroviral Adherence and Maximal Viral Control," *HIV/AIDS—Research and Palliative Care*, 2012; 4:125-133
45. Silverberg M, Leyden W, Stewart C, Ralston J, **Horberg M**, Carzasty S, Grothaus L, Catz S, "Change in Adherence to Antiretrovirals After Initial Use of an Electronic Shared Medical Record Among HIV-Infected Individuals," *Clinical Medicine & Research*, 2012; 10(3): 144-145.
46. Althoff K, Buchacz K, Hall HI, Zhang J, Hanna D, Rebeiro P, Gange S, Moore R, Kitahata M, Gebo K, Martin J, Justice A, **Horberg M**, Hogg R, Sterling T, Cescon A, Klein M, Thorne J, Crane H, Mugavero M, Napravnik S, Kirk G, Jacobson L, Brooks J, for the NA-ACCORD of IeDEA, "US Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Loads and CD4 T-Lymphocyte Counts among HIV-Infected Persons, 2000-2008," *Annals of Internal Medicine*, 2012; 157:325-335
47. Chao C, Leyden WA, Xu L, **Horberg M**, Klein D, Towner WJ, Quesenberry CP Jr, Abrams DI, Silverberg MJ. "Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons," *AIDS*, 2012; 26(17):2223-31
48. **Horberg M**, Raymond B, "Financial Policy Issues for PrEP: Practical Aspects of Cost and Access to Insurance," *American Journal of Preventive Medicine*, 2012 ; 44(1S2):S125–S128
49. Justice A, Modur S, Tate J, Althoff K, Jacobson L, Gebo K, Kitahata M, **Horberg M**, Brooks J, Buchacz K, Rourke S, Rachlis A, Napravnik S, Eron J, Saag M, Moore R, Kirk G, Bosch R, Rodriguez B, Hogg B, Thorne J, Goeder J, Klein M, Gill M, Deeks S, Sterling T, Anastos K, Gange S for The NA-ACCORD and VACS Project Teams, "Predictive Accuracy of the Veterans Aging Cohort Study (VACS) Index for Mortality with HIV Infection: a North America Cross Cohort Analysis," *JAIDS*, 2012; November 26 e-pub ahead of print; 2013 62(2):149-163.
50. Habel L, Ray GT, Silverberg M, **Horberg M**, Yawn B, Castillo A, Quesenberry C, Li Y, Sadier P, Tran T, "The Epidemiology of Herpes Zoster in Patients with Newly Diagnosed Cancer," *Cancer Epidemiology, Biomarkers & Prevention*, 2012; 22(1); 82–90
51. Rebeiro P, Althoff K, Buchacz K, Gill MJ, **Horberg M**, Krentz H, Moore R, Sterling T, Brooks J, Gebo K, Hogg R, Klein M, Martin J, Mugavero M, Rourke S, Thorne J, Gange, S, "Retention among North American HIV-Infected Persons in Clinical Care, 2000-2008," *JAIDS*, 2013; 62 (3): 356–362
52. DeLorenze G, **Horberg M**, Silverberg M, Tsai A-L, Quesenberry C, Baxter R, "Annual Incidence of MRSA Infection among HIV-Infected and non-HIV-infected Patients: 16 Years of Surveillance in a Large Health Plan," *Epidemiology and Infection*, 2013, 141(11):2392-402
53. Hanna D, Buchacz K, Gebo K, Hessol N, **Horberg M**, Jacobson L, Kirk G, Kitahata M, Korthuis PT, Moore R, Napravnik S, Patel P, Silverberg M, Sterling T, Willig J, Lau B, Althoff K, Crane H, Collier A, Thorne J, Gill MJ, Klein M, Martin J, Rodriguez B, Burke S, Gange S, for the NA-ACCORD of IeDEA, "Trends and Disparities in Antiretroviral Therapy Initiation and Virologic Suppression among Newly

Treatment-Eligible HIV-Infected Individuals in North America, 2001-2009," *Clinical Infectious Diseases*, 2013; 56(8):1174-82

54. Miller V, **Horberg M**, "Getting to Normal -- Are we there yet?" (editorial), *AIDS*, 2013; 27(6):1027-1028
55. Ralston J, Silverberg M, Grothaus L, Leyden W, Ross T, Stewart C, Carzasty S, **Horberg M**, Catz S, "Use of web-based shared medical records among patients with HIV," *American Journal of Managed Care*, 2013;19(4):e114-24 .
56. Mayer K, Gazzard B, Zuniga J, Amico KR, Anderson J, Azad Y, Cairns G, Dedes N, Duncombe C, Fidler S, Granich R, **Horberg M**, McCormack S, Montaner J, Rees H, Schackman B, Sow P, "Controlling the HIV Epidemic with Antiretrovirals: IAPAC Consensus Statement on Treatment as Prevention and Preexposure Prophylaxis," *Journal of International Association of Providers in AIDS Care*, 2013; 12(3): 208-216.
57. **Horberg M**, Hurley L, Klein D, Silverberg M, Quesenberry C, Mugavero M, "Missed Office Visits and Risk of Mortality among HIV Subjects in a Large Healthcare System," *AIDS, Patient Care and STDs*, 2013; 27(8):442-9
58. Meenan R, **Horberg M**, Silverberg M, Chun C, Williams A, McBurnie MA, Keast E, Leyden W, Xu L, Vijayadeva V, Antoniskis D, "PS2-20: Developing New Quality Measures for HIV Care Using the Electronic Medical Record," *Clinical Medicine and Research*, 2013: 11(3): 160.
59. Aberg J, Gallant J, Ghanem K, Emmanuel P, Zingman B, **Horberg M**, "Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America," *Clinical Infectious Diseases*, 2014; 58(1):e1-e34.
60. Aberg J, Gallant J, Ghanem K, Emmanuel P, Zingman B, **Horberg M**, "Executive Summary: Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America," *Clinical Infectious Diseases*, 2014; 58(1):1-10.
61. Hanna D, Buchacz K, Gebo K, Hessel N, **Horberg M**, Jacobson L, Kirk G, Kitahata M, Korthuis PT, Moore R, Napravnik S, Patel P, Silverberg M, Sterling T, Willig J, Collier A, Samji H, Thorne J, Martin J, Rodriguez B, Stuart E, Gange S, for the NA-ACCORD of IeDEA, "Association Between U.S. State AIDS Drug Assistance Program (ADAP) Features and HIV Antiretroviral Therapy Initiation, 2001-2009," *PLOS ONE*, 2013; 8(11):e78952.
62. Silverberg M, Leyden W, Xu L, **Horberg M**, Chao C, Towner W, Hurley L, Quesenberry C, Klein D, "Immunodeficiency and Risk of Myocardial Infarction among HIV-Positive Individuals with Access to Care," *JAIDS*, 2014: 65(2): 160-166.
63. Linas B, Hu H, Carter D, **Horberg M**, "Hepatitis C screening trends in a large integrated health system," *American Journal of Medicine*, 2014; 127(5):398-405.
64. Althoff K, Rebeiro P, Brooks J, Buchacz K, Gebo K, Martin J, Hogg R, Thorne J, Klein M, Gill MJ, Sterling T, Yehia B, Justice A, Gange S, Moore R, Kitahata M, **Horberg M**, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Disparities in the quality of HIV care when using US Department of Health and Human Services Indicators", *Clinical Infectious Diseases*, 2014; 58(8):1185-9
65. Maeda J, Lee K, **Horberg M**, "Comparative Health Systems Research among Integrated Delivery Systems and Managed Care Organizations: A Systematic Review," *Permanente Medical Journal*, 2014; 18(3):66-77

66. Tran T, Ray GT, **Horberg M**, Yawn B, Castillo A, Saddier P, Habel L, "Complications of Herpes Zoster in Cancer Patients," *Scandinavian Journal of Infectious Diseases*, 2014; 46(7):528-32
67. Marcus J, Chao C, Leyden W, Xu L, Klein D, **Horberg M**, Towner W, Quesenberry C, Abrams D, Van Den Eeden S, Silverberg M, "Prostate Cancer Incidence and Prostate-Specific Antigen Testing among HIV-Positive and HIV-Negative Men," *JAIDS*, 2014;66(5):495-502
68. Rodriguez C, **Horberg M**, "HIV Testing, Staging, and Evaluation," *Infectious Disease Clinics of North America*, 2014 Sep;28(3):339-353
69. DeLorenze G, Tsai A-L, **Horberg M**, Quesenberry C, "Cost of care for HIV-infected patients with co-occurring substance use disorder or psychiatric disease: report from a large, integrated health plan," *AIDS Research and Treatment*, 2014; 2014:570546
70. Marcus J, Leyden W, Chao C, Chow F, **Horberg M**, Hurley L, Klein D, Quesenberry C, Towner W, Silverberg M, "HIV Infection and Incidence of Ischemic Stroke," *AIDS*, 2014; 28(13):1911-9
71. Abraham A, Althoff K, Jing Y, Estrella M, Kitahata M, Wester W, Bosch R, Crane H, Eron J, Gill MJ, **Horberg M**, Justice A, Klein M, Krishnasami Z, Mayor A, Moore R, Palella F, Parikh C, Silverberg MJ, Golub E, Jacobson L, McKaig R, Napravnik S, Rodriguez B, and Lucas G for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), "End Stage Renal Disease Among HIV-Infected Adults in North America," *Clinical Infectious Diseases*, 2015; 60(6):941-9
72. Rebeiro P, **Horberg M**, Gange S, Gebo K, Yehia B, Brooks J, Buchacz K, Silverberg M, Gill J, Moore R, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Strong agreement of Nationally Recommended Retention Measures from the Institute of Medicine and the Department of Health and Human Services: a Cross-Sectional Study," *PLOS ONE*, 2014; Nov 6;9(11):e111772
73. Marcus J, Leyden W, Chao C, Xu L, Quesenberry C, Tien P, Klein D, Towner W, **Horberg M**, Silverberg M, "Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status," *AIDS, Patient Care and STDs*, 2015; July 2015, 29(7): 370-378.
74. Marcus JL, Chao C, Leyden W, Xu L, Yu J, **Horberg M**, Klein D, Towner W, Quesenberry C, Abrams D, Silverberg M, "Survival Among HIV-Positive and HIV-Negative Individuals with Common Non-AIDS-Defining Cancers," *Cancer Epidemiol Biomarkers Prev.*, 2015; e-pub ahead of print
75. Maeda J, Bradley J, Eissler S, LoBrano M, Rubin M, Gay M, **Horberg M**, Loftus B, "Expanding Access to Care and Improving Quality in the Mid-Atlantic Safety Net Clinics: Kaiser Permanente's Community Ambassador Program," *The Permanente Journal*, 2015; Spring;19(2):22-7
76. Klein D, Leyden W, Xu L, Chao C, **Horberg M**, Towner W, Hurley L, Marcus J, Quesenberry C, Silverberg M "Declining Relative Risk for Myocardial Infarction among HIV-Positive Compared with HIV-Negative Individuals with Access to Care," *Clinical Infectious Diseases*, 2015; Apr 15;60(8):1278-80
77. Saberi P, Catz S, Leyden W, Stewart C, Ralston J, **Horberg M**, Grothaus L, Silverberg M, "Antiretroviral Therapy Adherence and Use of an Electronic Shared Medical Record among People Living with HIV," *AIDS and Behavior*, 2015; e-pub ahead of print
78. Yehia B, Rebeiro P, Althoff K, Agwu A, **Horberg M**, Samji H, Napravnik S, Mayer K, Buchacz K, Tedaldi E, Silverberg M, Thorne J, Burchell A, Rourke S, Rachlis A, Mayor A, Gill M, Zinski A, Ohl M, Anastos K, Abraham A, Moore R, Gange S, Gebo K for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "The Impact of Age on Retention in Care and Viral Suppression," *JAIDS*, 2015 Apr 1;68(4):413-9

79. Silverberg M, Lau B, Achenbach C, Jing Y, Althoff K, D'Souza G, Engels E, Hessel N, Brooks J, Burchell A, Gill MJ, Goeder J, Hogg R, **Horberg M**, Kirk G, Kitahata M, Korthuis P, Mathews W, Mayor A, Modur S, Napravnik S, Novak R, Patel P, Rachlis A, Sterling T, Willig J, Justice A, Moore R, Dubrow R for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Cumulative Incidence of Cancer among HIV-infected Individuals in North America," *Annals of Internal Medicine*, 2015; 163(7):507-518.
80. **Horberg M**, "HIV Quality Measures and Outcomes—The Next Phase," *Clinical Infectious Diseases*, 2016; Jan 15; 62(2):240-1.
81. Koethe J, Jenkins C, Lau B, Shepherd B, Justice A, Tate J, Buchacz K, Napravnik S, Mayor A, **Horberg M**, Blashill A, Willig A, Wester CW, Gill MJ, Thorne JE, Klein M, Eron J, Moore R, Sterling T for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Rising Obesity Prevalence and Weight Gain among Adults Starting Antiretroviral Therapy in the United States and Canada, 1998 to 2010," *AIDS Res Hum Retroviruses*, 2015 Sep 9; e-pub ahead of print
82. **Horberg M**, Hurley L, Towner W, Kadlecik P, Antoniskis A, Mogyoros M, Brachman P, Remmers C, Gambatese R, Blank J, Ellis C, Silverberg M, "The HIV Care Cascade Measured Over Time and by Age, Sex, and Race in a Large National Integrated Care System," *AIDS, Patient Care, and STDs*, 2015; 11: 582-590.
83. Marcus JL, Neugebauer R, Leyden W, Chao C, Xu L, Quesenberry C, Klein D, Towner W, **Horberg M**, Silverberg M, "Use of abacavir and risk of cardiovascular disease among HIV-infected individuals", *JAIDS*, 2015; e-pub ahead of print
84. Gold R, Hollombe C, Bunce A, Nelson C, Davis JV, Cowburn S, Perrin N, DeVoe J, Mossman N, Boles B, **Horberg M**, Dearing J, Jaworski V, Cohen D, Smith D, "Study Protocol for "Study of Practices Enabling Implementation and Adaptation in the Safety Net (SPREAD-NET)": A Pragmatic Trial Comparing Implementation Strategies," *Implementation Science*, 2015; 10(1): 144-152.
85. Rebeiro P, Althoff K, Lau B, Gill MJ, Abraham A, **Horberg M**, Kitahata M, Yehia B, Samji H, Brooks J, Buchacz K, Napravnik S, Silverberg M, Rachlis A, Gebo K, Sterling T, Moore R, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Laboratory Measures as Proxies for Primary Care Encounters: Implications for Quantifying Clinical Retention among HIV-Infected Adults in North America," *American Journal of Epidemiology*, 2015; Dec 1;182(11):952-60
86. Althoff K, Rebeiro P, Hanna D, Padgett D, **Horberg M**, Grinsztejn B, Abraham A, Hogg R, Gill MJ, Wolff M, Mayor A, Rachlis A, Williams C, Sterling T, Kitahata M, Buchacz K, Thorne J, Cesar C, Cordero F, Rourke S, Madero J, Pape J, Cahn P, McGowan C, "A picture is worth a thousand words: Maps of HIV indicators to inform research, programs, and policy, from NA-ACCORD and CCASAnet clinical cohorts," *Journal of the International AIDS Society*, 2016 Apr 4;19(1):20707.
87. Marcus J, Chao C, Leyden W, Xu L, Quesenberry C, Klein D, Towner W, **Horberg M**, Silverberg M, "Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals with Access to Care: A Cohort Study," *JAIDS*, 2016; e-pub ahead of print
88. Gold R, Esterberg E, Hollombe C, Arkind J, Vakarcis PA, Tran H, Burdick T, DeVoe JE, **Horberg M**, "Low Back Imaging When not Indicated: A Descriptive Cross-System Analysis," *Permanente Medical Journal*, 2016 Spring;20(2):25-33
89. Rebeiro P, Gange S, **Horberg M**, Abraham A, Napravnik S, Samji H, Yehia B, Althoff K, Moore R, Kitahata M, Sterling T, Curriero F, "Geographic Variations in Retention in Care among HIV-Infected Adults in the United States," *PLOS ONE*, 2016; Jan 11;11(1):e0146119

90. Paolino A, McGlynn E, Lieu T, Nelson A, Prausnitz S, **Horberg M**, Arterburn D, Gould M, Laws R, Steiner R, "Building a Governance Strategy for CER: The Patient Outcomes Research to Advance Learning (PORTAL) Network Experience," *EGEMS*, 2016 Mar 28;4(2):1216
91. Koethe J, Jenkins C, Lau B, Shepherd B, Wester W, Rebeiro P, Silverberg M, Thorne J, Gill J, Mayor A, Willig A, Bosch R, **Horberg M**, Justice A, Sterling T, Moore R, "Higher Time-Updated Body Mass Index: Association with Improved CD4+ Cell Recovery of HIV Treatment," *JAIDS*, 2016; 73 (2): 197-204
92. Wong C, Gange S, Buchacz K, Moore RD, Justice A, **Horberg M**, Gill MJ, Koethe J, Rebeiro P, Silverberg M, Palella F, Patel P, Kitahata M, Crane H, Abraham A, Samji H, Napravnik S, Ahmed T, Thorne J, Bosch R, Mayor A, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension among North American HIV-Infected Adults, 2000-2013," *Clinical Infectious Diseases*, 2017; 64(4): 459-467.
93. Koenig C, Fischer H, Daley M, Ferrara A, **Horberg M**, Waitzfelder B, Young D, Gould M, "Interacting effects of obesity, race, ethnicity and sex on the incidence and control of adult-onset asthma," *Allergy, Asthma & Clinical Immunology*, 2016; 12:50.
94. Marcus J, Baxter R, Leyden W, Muthulingam D, Yee A, **Horberg M**, Klein D, Towner W, Chao C, Quessenberry C, Silverberg M, "Invasive Pneumococcal Disease among HIV-Infected and HIV-Uninfected Adults in a Large Integrated Healthcare System," *AIDS, Patient Care, and STDs*, 2016; 30 (10): 463-470
95. Young D, Waitzfelder B, Arterburn D, Nichols G, Ferrara A, Koenig C, Yamamoto A, Daley M, Bessesen D, Sherwood N, **Horberg M**, Lewis K, "Cohort Profile: The Patient Outcomes Research to Advance Learning (PORTAL) Network Adult Overweight/Obesity Cohort: Its Development and Description," *JMIR Research Protocols*, 2016; 5(2): e87.
96. Dubrow R, Qin L, Lin H, Hernández-Ramírez RU, Neugebauer RS, Leyden W, Althoff KN, Achenbach CJ, Hessel NA, Modur SP, D'Souza G, Bosch RJ, Grover S, **Horberg M**, Kitahata MM, Mayor AM, Novak RM, Rabkin CS, Sterling TR, Goedert JJ, Justice AC, Engels EA, Moore RD, Silverberg MJ, "Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada," *JAIDS*, 2017 Apr 7. [Epub ahead of print]
97. Rebeiro P, Abraham A, **Horberg M**, Althoff K, Yehia B, Buchacz K, Lau B, Sterling T, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Sex, Race, and HIV Risk Disparities in Discontinuity of HIV Care after Antiretroviral Therapy Initiation in the United States and Canada," *AIDS, Patient Care, and STDs*, 2017 Mar; 31(3):129-144.
98. Muzaale A, Althoff K, Sperati CJ, Abraham A, Kucirka L, Massie A, Kitahata M, **Horberg M**, Justice A, Fischer M, Silverberg M, Butt A, Boswell S, Rachlis A, Mayor A, Gill MJ, Eron J, Napravnik S, Dorzd D, Martin J, Bosch R, Durand C, Locke J, Moore R, Lucas G, Segev D, "Risk of End Stage Renal Disease in HIV-Positive Potential Live Kidney Donors," *American Journal of Transplantation*, 2017; 17(7): 1823-1832
99. Gonsalves G, Paltiel A, Cleary P, Gill MJ, Kitahata M, Rebeiro P, Silverberg MJ, **Horberg M**, Hall HI, Abraham A, Kaplan E, "A Flow Based Model of the HIV Care Continuum in the United States," *JAIDS*, 2017; 75(5): 548-553.
100. Kanwal F, Bacon B, Beste L, Brill J, Gifford A, Gordon S, **Horberg M**, Manthey J, Reau N, Rustgi V, Younossi Z, "Hepatitis C Virus Infection Care Pathway-A Report from the American Gastroenterological Association Institute HCV Care Pathway Work Group," *Gastroenterology*, 2017; 152(6): 1588-1598.

101. Chen R, Scherzer R, Hsue P, Jotwani V, Estrella M, **Horberg M**, Grunfeld C, Shlipak M, “Association of Tenofovir Use with Risk of Incident Heart Failure in HIV-infected Patients: A Retrospective Cohort Study,” *Journal of the American Heart Association*, 2017; 6(4): pii: e005387.
102. Nichols G, **Horberg M**, Koebnick C, Young D, Waitzfelder B, Sherwood N, Daley M, Ferrara A, “Cardiometabolic Risk Factors Among 1.3 Million Individuals Without Diabetes Affected by Overweight or Obesity,” *Preventing Chronic Disease*, 2017; 14: E22
103. Marcus J, Leyden W, Chao C, **Horberg M**, Klein D, Quesenberry C, Towner W, Silverberg M, “Immunodeficiency, AIDS-Related Pneumonia, and Risk of Lung Cancer among HIV-Infected Individuals,” *AIDS*, 2017; 31(7): 989-993.
104. Wong C, Gange S, Buchacz K, Moore R, Justice A, **Horberg M**, Gill M, Koethe J, Rebeiro P, Silverberg M, Palella F, Patel P, Kitahata M, Crane H, Abraham A, Samji H, Napravnik S, Ahmed T, Thorne J, Bosch R, Mayor A, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “First Occurrence of Diabetes, Chronic Kidney Disease, and Hypertension among North American HIV-Infected Adults, 2000-2013,” *Clinical Infectious Diseases*, 2017; 64(4): 459-467.
105. Wong C, Gange S, Moore R, Justice A, Buchacz K, Abraham A, Rebeiro P, Koethe J, Martin J, **Horberg M**, Boyd C, Kitahata M, Crane H, Gebo K, Gill MJ, Silverberg M, Palella F, Patel P, Samji H, Thorne J, Rabkin C, Mayor A, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Multimorbidity among Individuals Living with HIV in the US,” *Clinical Infectious Diseases*, 2018; 66(8): 1230-1238.
106. Chi F, Green C, Hinman A, Mertens J, Beck A, **Horberg M**, Weisner C, Campbell C, “Patient and System Characteristics Associated with performance on the HEDIS Measures of Alcohol and Other Drug Treatment Initiation and Engagement,” *Journal of Addiction Medicine*, 2018; e-pub ahead of print
107. Jonas MC, Loftus B, **Horberg M**, “The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System’s Perspective,” *Infectious Disease Clinics of North America*, 2018; 32(2): 418-493.
108. Silverberg M, Leyden W, Leibowitz A, Hare C, Jang H, Sterling S, Catz S, Parthasarathy S, **Horberg M**, Satre D, “Factors Associated with Hazardous Alcohol Use and Motivation to Reduce Drinking among HIV Primary Care Patients: Baseline Findings from the Health & Motivation Study,” *Addictive Behaviors*, 2018; 84: 110-117.
109. Yarborough B, Chi F, Green C, Hinman A, Mertens J, Beck A, **Horberg M**, Weisner C, Campbell C, “Patient and System Characteristics Associated with performance on the HEDIS Measures of Alcohol and Other Drug Treatment Initiation and Engagement,” *Journal of Addiction Medicine*, 2018; March 19; e-pub ahead of print
110. Young D, Fischer H, Arterburn D, Bessesen D, Cromwell L, Daley M, Desair J, Ferrara A, Fitzpatrick S, **Horberg M**, Koebnick C, Nau C, Oshiro C, Waitzfelder B, Yamamoto A, “Associations of Overweight/Obesity and Socioeconomic Status with Hypertension Prevalence Across Racial and Ethnic Groups,” *The Journal of Clinical Hypertension*, 2018; 20(3): 532-540.
111. Altekruse S, Shiels M, Modur S, Land S, Crothers K, Kitahata M, Thorne J, Mathews W, Fernandez-Santos D, Mayor A, Gill J, **Horberg M**, Brooks J, Moore R, Silverberg M, Althoff K, Engels E, “Cancer Burden Attributable to Cigarette Smoking among HIV-Infected People in North America,” *AIDS*, 2018; 32(4): 513-521.
112. Elion RA, Althoff KN, Zhang J, Moore RD, Gange SJ, Kitahata MM, Crane HM, Drozd DR, Stein JH, Klein MB, Eron JJ, Silverberg MJ, Mathews WC, Justice AC, Sterling TR, Rabkin CS, Mayor AM, Klein DB, **Horberg M**, Bosch RJ, Eyawo O, Palella FJ Jr; North American AIDS Cohort Collaboration on

Research and Design of leDEA, “Recent Abacavir Use Increases Risk of Type 1 and Type 2 Myocardial Infarctions among Adults with HIV,” *JAIDS*, 2018; 78(1): 62-72.

113. **Horberg M**, Oakes A, Hurley L, Towner W, Chao C, Silverberg M, Chantra J, Ellis C, Quesenberry C, “Association of Raltegravir Use with Long-Term Health Outcomes in HIV-Infected Patients: An Observational Post-Licensure Safety Study in a Large Integrated Healthcare System,” *HIV Clinical Trials*, 2018; Oct;19(5):177-187
114. Bradley H, Althoff K, Buchacz K, Boswell S, Brooks J, Gill MJ, **Horberg M**, Kitahata M, Marconi V, Mayor A, Moore R, Mugavero M, Napravnik S, Paz-Bailey G, Prejean J, Rebeiro P, Rentsch C, Shouse RL, Sullivan P, Thorne J, Yehia B, Rosenberg E, “Viral Suppression among Persons in HIV Care during 2009-2013: Sampling Bias in Medical Monitoring Project (MMP) Surveillance Estimates,” *Annals of Epidemiology*, 2019; 31: 3-7.
115. **Horberg M**, Blank J, Rubenstein K, Certa J, Hurley L, Kadlecik P, Klein D, Silverberg M, “Impact of Alternative Encounter Types on HIV Viral Suppression Rates in an Integrated Health System,” *AIDS, Patient Care, and STDs*, 2018; 32(11): 425-431.
116. Eby J, Lane M, **Horberg M**, Gentry C, Coffin S, Ray A, Sheridan K, Bratzler D, Wheeler D, Sarumi M, Barlam T, Kim T, Rodriguez A, Nahass R, “How Do You Measure Up: Quality Measurement for Improving Patient Care and Establishing the Value of Infectious Diseases Specialists,” *Clinical Infectious Diseases*, 2018; (e-Pub ahead of print)
117. Tartof S, Hsu J-W, Wei R, Rubenstein K, Hu H, Arduino JM, **Horberg M**, Derose S, Qian L, Rodriguez C, “Kidney Function Decline in Patients with Chronic Kidney Disease and Untreated Hepatitis C Infection,” *Clinical Journal of the American Society of Nephrology*, 2018; 13(10): 1471-1478.
118. Grover S, Desir F, Jing Y, Bhatia RK, Trifiletti D, Swisher-McClure S, Kobie J, Moore R, Rabkin C, Silverberg M, Salters K, Mathews W, Gill MJ, Thorne JE, Castilho J, Kitahata M, **Horberg M**, Achenbach C, Mayor A, Althoff K, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Reduced Cancer Survival Among Adults with HIV and AIDS-Defining Illnesses Despite No Difference in Cancer Stage at Diagnosis,” *Journal AIDS*, 2018; 79(4): 421-429.
119. Desir F, Lesko C, Moore R, **Horberg M**, Wong C, Crane H, Silverberg M, Thorne J, Rachlis B, Rabkin C, Mayor A, Mathews W, Althoff K, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “One Size Fits (n)One: The Influence of Sex, Age, and Sexual Human Immunodeficiency Virus (HIV) Acquisition Risk on Racial/Ethnic Disparities in the HIV Care Continuum in the United States,” *Clinical Infectious Diseases*, 2018; (e-Pub ahead of print)
120. Ter-Minassian M, Lanzkron S, Derus A, Brown E, **Horberg M**, “Quality Metrics and Health Care Utilization for Adult Patients with Sickle Cell Disease,” *Journal of the National Medical Association*, 2018; (e-Pub ahead of print)
121. Rodriguez C, Rubenstein K, Linas B, Hu H, **Horberg M**, “Increasing Hepatitis C Screening in a Large Integrated Health System: Science and Policy in Concert,” *American Journal of Managed Care*, 2018; 24(5): e134-e140.
122. Yanik E, Hernandez-Ramirez R, Qin L, Lin H, Leyden W, Neugebauer R, **Horberg M**, Moore R, Mathews W, Justice A, Hessol N, Mayor A, Gill M, Brooks J, Sun J, Althoff K, Engels E, Silverberg M, Dubrow R, “Brief Report: Cutaneous Melanoma Risk among People with HIV in the United States and Canada,” *Journal AIDS*, 2018; 78(5): 499-504.
123. Vupputuri S, Rubenstein K, Derus A, Loftus B, **Horberg M**, “Factors Contributing to Racial Disparities in Influenza Vaccinations,” *PLoS One*, 2019; 14(4): e0213972.

124. Hechter R, **Horberg M**, Weisner C, Campbell C, Contreras R, Chen L, Yarborough JH, Lapham G, Haller I, Ahmedani B, Binswanger I, Kline-Simon A, Satre D, "Healthcare Effectiveness Data and Information Set (HEDIS) Measures of Alcohol and Drug Treatment Initiation and Engagement among People Living with Human Immunodeficiency Virus (HIV) and Patients without an HIV Diagnosis," *Substance Abuse*, 2019; (e-pub ahead of print)
125. Lewis KH, Fischer H, Ard J, Barton L, Bessesen D, Daley M, Desai J, Fitzpatrick S, **Horberg M**, Koebnick C, Oshiro C, Yamamoto A, Young D, Arterburn D, "Safety and Effectiveness of Long-Term Phentermine Use: Clinical Outcomes and Electronic Health Record Cohort," *Obesity (Silver Spring)*, 2019; 27(4): 591-602.
126. Althoff K, Gebo K, Moore R, Boyd C, Justice A, Wong C, Lucas G, Klein M, Kitahata M, Crane H, Silverberg M, Gill MJ, Mathews W, DuBrow R, **Horberg M**, Rabkin C, Klein D, Lo Re V, Sterling T, Desir F, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the US and Canada: a Collaboration of Cohort Studies," *Lancet HIV*, 2019; 6(2) e93-e104.
127. Poteat T, Hanna DB, Rebeiro PF, Klein M, Silverberg MJ, Eron JJ, **Horberg M**, Kitahata MM, Mathews WC, Mattocks K, Mayor A, Rich AJ, Reisner S, Thorne J, Moore RD, Jing Y, Althoff KN; North American AIDS Cohort Collaboration On Research and Design of the International Epidemiology Databases to Evaluate AIDS, "Characterizing the Human Immunodeficiency Virus Care Continuum Among Transgender Women and Cisgender Women and Men in Clinical Care: A Retrospective Time-series Analysis," *Clinical Infectious Disease*, 2019, (e-pub ahead of print)
128. Zhu Y, Sidell M, Arterburn D, Daley M, Desai J, Fitzpatrick S, **Horberg M**, Koebnick C, McCormick E, Oshiro C, Young D, Ferrara A, "Racial/Ethnic Disparities in the Prevalence of Diabetes and Prediabetes by Body Mass Index: Patient Outcomes Research to Advance Learning (PORTAL) Multi-Site Cohort of Adults in the US," *Diabetes Care*, 2019 (e-pub ahead of print)
129. Satre D, McNeely J, Hare B, Leibowitz A, Volberding P, Weisner C, Silverberg M, Sally S, Anderson A, **Horberg M**, Levine-Hall T, Flamm J, "Implementing Electronic Substance Use Disorder and Depression and Anxiety Screening and Behavioral Interventions in Primary Care Clinics Serving People with HIV: Protocol for Promoting Access to Care Engagement (PACE) Trial," *Contemporary Clinical Trials*, 2019; Sep;84:105833
130. Levy M, Monroe A, **Horberg M**, Benator D, Molock S, Doshi R, Powers-Happ L, Castel A, on behalf of the DC Cohort Executive Committee, "Pharmacologic Treatment of Psychiatric Disorders and Time with Unsuppressed HIV Viral Load in a Clinical HIV Cohort," *JAIDS*, 2019. (e-pub ahead of print)
131. Satre DD, Leibowitz AS, Leyden W, Catz SL, Hare CB, Jang H, Lam JO, Bryant KJ, Weisner CM, Sterling SA, **Horberg M**, Volberding P, Silverberg MJ, "Interventions to Reduce Unhealthy Alcohol Use among Primary Care Patients with HIV: the Health and Motivation Randomized Clinical Trial," *Journal of General Internal Medicine*, 2019; (e-pub ahead of print)
132. Lo Re V 3rd, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, **Horberg M**, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN; North American AIDS Cohort Collaboration on Research and Design of IeDEA, "Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients," *JAIDS*, 2019; Sep 1;82(1):71-8
133. Hernández-Ramírez RU, Qin L, Lin H, Leyden W, Neugebauer RS, Althoff KN, Hessel NA, Achenbach CJ, Brooks JT, Gill MJ, Grover S, **Horberg M**, Li J, Mathews WC, Mayor AM, Patel P, Rabkin CS, Rachlis A, Justice AC, Moore RD, Engels EA, Silverberg MJ, Dubrow R; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, "Association of immunosuppression and HIV viremia with anal cancer risk in persons

living with HIV in the United States and Canada,” *Clinical Infectious Disease*, 2019 (e-pub ahead of print)

134. Althoff K, Wong C, Hogan B, Desir F, You B, Humes E, Zhang J, Jing Y, Modur S, Lee J, Freeman A, Kitahata M, van Rompey S, Mathews WC, **Horberg M**, Silverberg M, Mayor A, Salters K, Moore R, Gange S for the North American AIDS Cohort Collaboration on Research and Design, “Mind the Gap: Observation Windows to Define Periods of Event Ascertainment in Longitudinal Electronic Medical Record Data,” *Annals of Epidemiology*, 2019; 33:54-63
135. Levy M, Monroe A, **Horberg M**, Benator D, Castel D, on behalf of the DC Cohort Executive Committee, “Is Low-Level Viraemia Associated with Serum Lipid Profiles among HIV Controllers?,” *HIV Medicine*, 2020; 21, e14-e16
136. Lam J, Levine-Hall T, Hood N, Alexeeff S, **Horberg M**, Young-Wolff K, Sterling S, Williams A, Weisner C, Satre D, Silverberg M, “Smoking and Cessation Treatment among Persons with and without HIV in an Integrated Health System,” *Drug and Alcohol Dependence*, 2020; 18:213:108128.
137. Happ L, Monroe A, Young H, Ma Y, Greenberg A, **Horberg M**, Castel A, “Individual- and Clinical-Level Factors Associated with Achieving Glycemic Control in a Large Cohort of People with HIV in Care—Washington, DC,” *JAIDS*, 2020; 85 (1): 113-122.
138. Marcus J, Leyden W, Alexeeff S, Anderson A, Hechter R, Hu H, Lam J, Towner W, Yuan Q, Silverberg M, **Horberg M**, “Comparison of Life Expectancy and Comorbidity-Free Life Expectancy of Insured Adults With and Without HIV, 2000-2016,” *JAMA Open*, 2020; 3(6): e207954.
139. Fitzpatrick S, Rosales A, Brown S, Arterburn D, Daley M, **Horberg M**, Koebnick C, Oshiro C, Young D, “Behavioral and Psychological Factors Associated with 5-Year weight Trajectories within the PORTAL Overweight/Obesity Cohort,” *Obesity Science and Practice*, 2020; 6(3): 272-281.
140. Spence A, Levy M, Monroe A, Castel A, Timpone J, **Horberg M**, Adams-Campbell L, Kumar P, “Cancer Incidence and Cancer Screening Practices among a Cohort of Persons Receiving HIV Care in Washington, DC,” *Journal of Community Health*, 2021; 46: 75-85.
141. Bourgi K, Jenkins C, Rebeiro P, Palella F, Moore R, Althoff K, Gill MJ, Rabkin C, Gange S, **Horberg M**, Margolick J, Li J, Wong C, Willig A, Lima V, Crane H, Thorne J, Silverberg MK, Kirk G, Mathews WC, Sterling, T, Lake J, “Weight Gain among Treatment-Naïve Persons with HIV Starting Integrase Inhibitors in a Large Observational Cohort in the United States and Canada,” *Journal of the International AIDS Society*, 2020; 23(4): e25484.
142. Opoku J, Doshi R, Castel A, Sorensen I, **Horberg M**, Allston A, Kharfen M, Greenber A, “Comparison of Clinical Outcomes of Persons Living with HIV by Enrollment Status in Washington, DC: Evaluation of a Large Longitudinal HIV Cohort Study,” *JMIR Public Health Surveillance*, 2020; 6(2): e16061.
143. George JM, Kuriakose S, Monroe A, Hou Q, Pau A, Masur H, Hadigan C, Castel A, **Horberg M**, on behalf of the DC Cohort Executive Committee, “Utilization of Direct Oral Anticoagulants in People with HIV: Observational Data from the DC Cohort,” *Clinical Infectious Diseases*, 2020; e-pub ahead of print.
144. Roriguez-Watson C, Rubenstein K, Jonas MC, Sun Y, **Horberg M**, Loftus B, “Hepatitis C Care Pathway Associated with Increased Screening, Confirmation, and Diagnosis Communication to Patients,” *Clinical Gastroenterology and Hepatology*, 2021 Mar;19(3):607-609.
145. Secco A, Akselrod H, Czeresnia J, Levy M, Byrne M, Monroe A, Lucar J, **Horberg M**, Castel A, Doshi R, Rivasplata H, Squires L, Parenti D, Benator D, on behalf of the DC Cohort Executive Committee, “Sexually Transmitted Infections in Person Living with HIV Infection and Estimated HIV

Transmission Risk; Trends over Time from the DC Cohort,” *Sexually Transmitted Infections*, 2020; 96(2): 89-95.

146. Gold R, Bunce A, Cowburn S, Davis J, Nelson J, Nelson C, Hicks E, Cohen D, **Horberg M**, Melgar G, Dearing J, Seabrook J, Mossman N, Blukley J, “Does Increased Implementation Support Improve Community Clinics’ Guidelines-Concordant Care? Results of a Mixed Methods, Pragmatic Comparative Effectiveness Trial,” *Implementation Science*, 2019, 14(1): 100.
147. Satre D, Sarovar V, Leyden W, Hare CB, Catz S, Bryant K, Williams E, Hojilla JC, **Horberg M**, Silverberg M, “Change in Days of Unhealthy Alcohol Use and Antiretroviral Therapy Adherence, HIV RNA Levels, and Condomless Sex: A Secondary Analysis of Clinical Trial Data,” *AIDS and Behavior*, 2020; 24(6): 1784-1792.
148. Monroe A, Happ L, Rayeed N, Ma Y, Jaurretche M, Terzian A, Trac K, **Horberg M**, Greenberg A, Castel A, on behalf of the DC Cohort Executive Committee, “Clinic-Level Factors Associated with Time to Antiretroviral Initiation and Viral Suppression in a Large Urban Cohort,” *Clinical Infectious Diseases*, 2019; e-pub ahead of print.
149. Saxon D, Iwamoto S, Mettenbrink C, McCormick E, Arterburn D, Daley M, Oshiro C, Koebnick C, **Horberg M**, Young D, Bessesen D, “Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009-2015,” *Obesity (Silver Spring)*, 2019; 27(12): 1975-1981.
150. Althoff K, Chandran A, Zhang J, Miranda W, Gange S, Sterling T, Gill MJ, Justice A, Palella F, Rebeiro P, Silverberg M, Mayor A, **Horberg M**, Thorne J, Rabkin C, Mathews WC, Klein M, Humes E, Lee J, Hogg R, Moore R, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Life-Expectancy Disparities Among Adults with HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model,” *American Journal of Epidemiology*, 2019; 188(12): 2097-2109
151. **Horberg M**, Certa J, Rubenstein K, Hurley B, Satre D, Kadlecik P, Silverberg MJ, “Beyond the HIV Care Continuum and Viral Suppression: Broadening the Scope of Quality Metrics for Total HIV Patient Care,” *AIDS, Patient Care, and STDs*, 2020; Nov;34(11):461-469.
152. Thompson M, **Horberg M** (co-lead authors), Agwu A, Colasanti J, Jain M, Short W, Singh T, Aberg J, “Primary Care Guidance for Persons with Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America,” *Clinical Infectious Diseases*, 2020; November 6, online ahead of print.
153. Satre D, Parthasarathy S, Silverberg M, **Horberg M**, Young-Wolff K, Willisams E, Volberding P, Campbell C, “Health Care Utilization and HIV Clinical Outcomes among Newly Enrolled Patients Following Affordable Care Act Implementation in A California Integrated Health System: A Longitudinal Study,” *BMC Health Services Research*, 2020; 20 (1): 1030-1042.
154. Davy-Mendez T, Napravnik S, Hogan B, Althoff K, Gebo K, Moore R, **Horberg M**, Silverberg M, Gill MJ, Crane H, Marconi V, Bosch R, Colasanti J, Sterling T, Mathews W, Mayor A, Nanditha N, Buchacz K, Li J, Rebeiro P, Thorne J, Nijhawan A, Van Duin D, Wohl D, Eron J, Berry S for the North American AIDS Cohort Collaboration on Research and Design, “Hospitalization Rates and Causes among Persons with HIV in the US and Canada,” *Journal of Infectious Diseases*, 2020; October 21, online ahead of print.
155. Silverberg M, Hood N, Levine-Hall T, Anderson A, Alexeeff S, Lam J, Slome S, Flamm J, Hare C, Ross T, Justice A, Sterne J, Williams A, Bryant K, Weisner C, **Horberg M**, Sterling S, Satre D, “Health System-Based Unhealthy Alcohol Use Screening and Treatment Comparing Demographically-Matched Participants With and Without HIV,” *Alcoholism Clinical and Experimental Research*, 2020; October 17, online ahead of print.

156. Isaac A, Swartz D, Miller M, Short D, Wilson E, Chaffo J, Watson E, Hu H, Petersen B, Bloom J, Neff N, Linders D, Salgado S, Locke J, **Horberg M**, “Lower Resource Utilization of Patients with Healed Diabetic Foot Ulcers During Participation in a Prevention Program with Foot Temperature Monitoring,” *BMJ Open Diabetes Research and Care*, 2020; October 8 (1): e001440.
157. Rebeiro P, Jenkins C, Bian A, Lake J, Bourgi K, Moore R, **Horberg M**, Matthews W, Silverberg M, Thorne J, Mayor A, Lima V, Palella F, Saag M, Althoff K, Gill MJ, Wong C, Klein M, Crane H, Marconi V, Shepherd B, Sterling T, Koethe J, “Risk of Incident Diabetes Mellitus, Weight Gain, and their Relationships with Integrase Inhibitor-Based Initial Antiretroviral Therapy among Persons with HIV in the US and Canada,” *Clinical Infectious Diseases*, 2020; Sept 16, online ahead of print.
158. Young D, Sidell M, Fitzpatrick S, Koebnick C, Nau C, Oshiro C, **Horberg M**, “Characteristics of Adults with Overweight and Obesity Who Have Not Attempted Weight Loss in the Prior 12 Months,” *Obesity Research & Clinical Practice*, 2020; (5): 449-455.
159. Wallace D, **Horberg M**, Benator D, Greenberg A, Castel A, Monroe A, Powers-Happ L, “Diabetes Mellitus Control in a Large Cohort of HIV-infected People in Care-Washington, DC,” *AIDS Care*, 2020; August 18, online ahead of print
160. Silverberg M, Leyden W, Hernandez-Ramirez R, Qin L, Lin H, Justice A, Hessel N, Achenbach C, D’Souza Gypsy A, Engels E, Althoff K, Mayor A, Sterling T, Kitahata M, Bosch R, Saag M, Rabkin C, **Horberg M**, Gill MJ, Grover S, Mathews C, Li J, Crane H, Gange S, Lau B, Moore R, Dubrow R, Neugebauer R, for the North American AIDS cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, “Timing of Antiretroviral Therapy Initiation and Risk of Cancer among Person with HIV,” *Clinical Infectious Diseases*, 2020; August 12, online ahead of print
161. Lu H, Cole S, Westreich D, Hudgens M, Adimora A, Althoff K, Silverberg M, Buchacz K, Li J, Edwards J, Rebeiro P, Lima V, Marconi V, Sterling T, **Horberg M**, Gill MJ, Kitahata M, Eron J, Moore R, for the North American AIDS cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, “Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens among Adults with Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada,” *Clinical Infectious Diseases*, 2020 August 11, online ahead of print
162. Doshi R, Byrne M, Levy M, Varga L, Kuo I, **Horberg M**, Castel A, Monroe A, on behalf of the DC Cohort Executive Committee, “Association of Substance Use Disorders with Mortality and Engagement in Care among a Clinical Cohort of People with HIV in Washington, DC,” *AIDS and Behavior*, 2021; e-pub ahead of print
163. Nassery N, **Horberg MA** (co-lead author), Rubenstein KB, Certa JM, Watson E, Somasundaram B, Shamim E, Townsend JL, Galiatsatos P, Pitts SI, Hassoon A, Newman-Toker DE. Antecedent treat-and-release diagnoses prior to sepsis hospitalization among adult emergency department patients: a look-back analysis employing insurance claims data using Symptom-Disease Pair Analysis of Diagnostic Error (SPADE) methodology. *Diagnosis (Berl)*. 2021 Feb 25. doi: 10.1515/dx-2020-0140. Epub ahead of print. PMID: 33650389.
164. Watanabe J, Simon G, **Horberg M**, Platt R, Hernandez A, Califf R, “When are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials?,” *Clinical Pharmacology & Therapeutics*, 2021; e-pub ahead of print
165. Franklin J, Platt R, Dreyer N, London A, Simon G, Watanabe J, **Horberg M**, Hernandez A, Califf R, “When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?,” *Clinical Pharmacology & Therapeutics*, 2021; e-pub ahead of print

166. Finch A, Crowell A, Bhatia M, Parameshwarappa P, Chang Y, Martinez J, **Horberg M**, “Exploiting Hierarchy in Medical Concept Embedding,” *JAMIA Open*, 2021 Mar 16;4(1):ooab022.
167. Davy-Mendez T, Napravnik S, Eron J, Cole S, Van Duin D, Wohl D, Gebo K, Moore R, Althoff K, Poteat T, Gill MJ, **Horberg M**, Silverberg M, Nanditha N, Thorne J, Berry S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, “Racial, Ethnic, and Gender Disparities in Hospitalizations among Persons with HIV in the United States and Canada, 2005-2015,” *AIDS*, 2021; e-pub ahead of print
168. Miller M, Watson E, **Horberg M**, Bhatia M, McCarthy R., “Patient Experience after Modifying Visit Delivery During the COVID-19 Pandemic,” *AJMC*, 2021 Feb 1;27(2):e54-e63
169. Lee J, Humes E, Hogan B, Buchacz K, Eron J, Gill MJ, Sterling T, Rebeiro P, Dias Lima V, Mayor A, Silverberg M, **Horberg M**, Moore R, Althoff K, for the North American AIDS cohort Collaboration on Research and Design, “CD4 Count at Entry into HIV Care and at Antiretroviral Therapy Prescription in the US, 2005-2018,” *Clinical Infectious Diseases*, 2020; e-pub ahead of print
170. Sun J, Althoff KN, Jing Y, **Horberg MA**, Buchacz K, Gill MJ, Justice AC, Rabkin CS, Goedert JJ, Sigel K, Cachay E, Park L, Lim JK, Kim HN, Lo Re V 3rd, Moore R, Sterling T, Peters MG, Achenbach CJ, Silverberg M, Thorne JE, Mayor AM, Crane HM, Kitahata MM, Klein M, Kirk GD; North American AIDS Cohort Collaboration on Research and Design of IeDEA,” *JAMA Netw Open*. 2021 Feb 1;4(2):e2037512
171. Satre DD, Levine-Hall T, Sterling SA, Young-Wolff KC, Lam JO, Alexeeff S, Hojilla JC, Williams A, Justice AC, Sterne J, Cavassini M, Bryant KJ, Williams EC, **Horberg MA**, Volberding P, Weisner C, Silverberg MJ. Satre DD, et al.,” The relationship of smoking and unhealthy alcohol use to the HIV care continuum among people with HIV in an integrated health care system” *Drug Alcohol Depend*. 2021 Feb 1;219:108481
172. Kim NH, Newcomb CW, Carbonari DM, Roy JA, Torgersen J, Althoff KN, Kitahata MM, Rajender Reddy K, Lim JK, Silverberg MJ, Mayor AM, **Horberg MA**, Cachay ER, Kirk GD, Sun J, Hull M, John Gill M, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Lo Re V 3rd, The North American Aids Cohort Collaboration On Research F, Of IeDEA, “Risk of Hepatocellular Carcinoma with Hepatitis B Viremia among HIV/Hepatitis B Virus-Coinfected Persons in North America.” *Hepatology*, 2021 Mar 29 (e-pub ahead of print)
173. Coburn SB, Shiels MS, Silverberg MJ, **Horberg MA**, Gill MJ, Brown TT, Visvanathan K, Connor AE, Napravnik S, Marcus JL, Moore RD, Mathews WC, Mayor AM, Sterling TR, Li J, Rabkin CS, D'Souza G, Lau B, Althoff KN; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiology Databases to Evaluate AIDS“, *J Acquir Immune Defic Syndr.*, 2021 May 1;87(1):663-670
174. **Horberg MA**, Nassery N, (co-lead author), Rubenstein KB, Certa JM, Watson E, Somasundaram B, Shamim E, Townsend JL, Galiatsatos P, Pitts SI, Hassoon A, Newman-Toker DE , “Rate of sepsis hospitalizations after misdiagnosis in adult emergency department patients: A look-forward analysis with administrative claims data using SPADE methodology in an integrated health system,” *Diagnosis (Berlin)*, 2021; e-pub ahead of print
175. Rahman V, **Horberg M**, Hu H, Vupputuri S, “Implementation of a Plant-Based Nutrition Program in a Large Integrated Health Care System: Results of a Pilot Program,” *J Primary Care and Community Health*, 2021; January-December 12: 21501327211053198.
176. Monroe A, Levy M, Greenberg A, Keruly J, Moore R, **Horberg M**, Kulie P, Mohanraj B, Kumar P, Castel A, on behalf of the DC Cohort Executive Committee, “Integrase Inhibitor Prescribing Disparities in the DC and Johns Hopkins HIV Cohorts,” *Open Forum Infectious Diseases*, 2021; July 27;8(8):ofab388.

177. McGinnis K, Justice A, Moore R, Sivlerberg M, Althoff K, Karris M, Lima V, Crane H, **Horberg M**, Klein M, Gange S, Gebo K, Mayor A, Tate J, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA and Veterans Aging Cohort Study, “Discrimination and Calibration of the VACS Index 2.0 for Predicting Mortality among People with HIV in North America,” *Clinical Infectious Diseases*, 2021; e-pub ahead of print
178. Edwards J, cole S, Breger T, Rudolph J, Filiatreau L, Buchacz K, Humes E, Rebeiro P, D’Souza G, Gill MJ, Silverberg M, Mathews C, **Horberg M**, Thorne J, Hall HI, Justice A, Marconi V, Lima V, Bosch R, Sterling T, Althoff K, Moore R, Saag M, Eron J, “Mortality among Persons Entering HIV Care Compared with the General US Population,” *Annals of Internal Medicine*, 2021; 174(4): 1197-1206.
179. Simon G, Platt R, Watanabe J, Bindman A, London A, **Horberg M**, Hernandez A, Califf R, “When Can we Rely on Real-World Evidence to Evaluate New Medical Treatments?,” *Clinical Pharmacology & Therapeutics*, 2021; e-pub ahead of print
180. Simon G, Bindman A, Dreyer N, Platt R, Watanabe J, **Horberg M**, Hernandez A, Califf R, “When Can We Trust Real-World Data to Evaluate New Medical Treatments?,” *Clinical Pharmacology & Therapeutics*, 2021; e-pub ahead of print
181. Davy-Mendez T, Napravnik S, Eron J, Cole S, Van Duin D, Wohl D, Gebo K, Moore R, Althoff K, Poteat T, Gill MJ, **Horberg M**, Silverberg M, Nanditha N, Thorne J, Berry S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, Current and Past Immunodeficiency are Associated with Higher Hospitalization Rates among Persons on Virologically Suppressive Antiretroviral Therapy for up to 11 Years,” *Journal Infectious Diseases*, 2021; 224(4): 657-666.
182. Finch A, Crowell A, Chang YC, Parameshwarappa P, Martinez J, **Horberg M**, “A Comparison of Attentional Neural Network Architectures for Modeling with Electronic Medical Records,” *JAMIA Open*, 2021; August 12, 4(3): ooab064.
183. Kasaie P, Stewart C, Humes E, Gerace L, Zhang J, Silverberg MJ, **Horberg M**, Rebeiro PF, Hyle E, Lima V, Wong C, Gill MJ, Gebo K, Moore, Kitahata M, Althoff K, “Projecting the Age-Distribution of Men who have Sex with Men Receiving HIV Treatment in the United States,” *Annals of Epidemiology*, 2021; October 7:S1047-2797(21)00281-7.
184. Nadison M, Flamm L, Roberts A, Staton T, Wiener L, Locke J, Bullock E, Loftus B, Carpenter C, Sadler M, **Horberg M**, “Kaiser Permanente’s Good Health & Great Hair Program: Partnering with Barbershops and Beauty Salons to Advance Health Equity in West Baltimore, Maryland,” *Journal of Public Health Management Practice*, 2021; e-pub ahead of print

In Press

1. Avula H, Ambrosy A, Silverberg M, Reynolds K, Towner W, Hechter R, **Horberg M**, Vupputuri S, Leong T, Leyden W, Harrison T, Lee K, Sung SH, Go A, “HIV Infection and Risks of Morbidity and Death in Adults with Incident Heart Failure,” *JAMA Cardiology*, 2020 (Submitted)
2. Althoff K, Stewart C, Humes E, Zhang J, Gerace L, Boyd C, Wong C, Justice A, Gebo K, Thorne J, Rubstova A, **Horberg M**, Silverberg M, Leng S, Rebeiro P, Moore R, Buchacz K, Kasale P, “The Shifting Age Distribution of People with HIV Using Antiretroviral Therapy in the United States, 2020 to 2030,” *AIDS*, 2021 (Submitted)
3. Gold R, Bunce A, Davis J, Nelson J, Cowburn S, Oakley J, Carney S, **Horberg M**, Dearing J, Melgar G, Bulkley J, Seabrook J, Cloutier H, “I Didn’t Know You Could Do That:’ A Pilot Assessment of EHR Optimizaiton Training,” *ACI Open*, 2021 (In Press)

4. **Horberg M**, Eberhart L, Bhatia M, Jonas C, Cherico-Hsii S, Tamrat Y, Bhandari B, Kadlecik P, Gahunia M, "Patient Demographics and the Utilization of a Novel Three Anatomic Site Testing Panel Including Rectal Self-Collection as Compared to Usual Care Testing," *Sexually Transmitted Diseases*, 2021 (Submitted)

Publications as a Collaborator (not as a named Author)

1. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H; BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. *N Engl J Med*. 2008 Jul 24;359(4):339-54.
2. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. *N Engl J Med*. 2008 Jul 24;359(4):355-65.
3. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams. Maraviroc for previously treated patients with R5 HIV-1 infection. *N Engl J Med*. 2008 Oct 2;359(14):1429-41.
4. Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. *N Engl J Med*. 2008 Oct 2;359(14):1442-55
5. Hauschild, B., Onaga, L., Miller, V. (on behalf of Horberg, M., et. al.), *Metrics and Evaluation Measures for Monitoring the Implementation of Routine HIV Testing in the U.S.*, Report of a Forum for Collaborative HIV Research Roundtable, December 14, 2009, available at www.hivforum.org
6. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B, Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY; BENCHMRK Study Teams. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase iii trials. *Clin Infect Dis*. 2010 Feb 15;50(4):605-12.
7. Althoff K, Justice A, Gange S, Deeks S, Saag M, Silverberg M, Gill M, Lau B, Napravnik S, Tedaldi E, Klein M, Gebo K for NA-ACCORD, "Virologic and Immunology Response to HAART, by Age and Regimen Class," *AIDS*, 2010; 24:000 e-pub ahead of print
8. Institute of Medicine, *HIV and Disability: Updating the Social Security Listings*, National Academies Press, 2010.
9. Institute of Medicine, *HIV Screening Access to Care: Exploring Barriers and Facilitators to Expanded HIV Testing*, National Academies Press, 2010.
10. Institute of Medicine, *Monitoring HIV Care in the United States: Indicators and Data Systems*, National Academies Press, 2012.
11. Eron J, Steigbigel RT, Cooper DA, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Strohmaier KM, Wan H, Barnard RJ, Nguyen

BY, Teppler H, for the BENCHMRK Study Teams, "Efficacy and Safety of Raltegravir for treatment of HIV for 5 Years in the BENCHMRK Studies: Final Results of Two Randomised, Placebo-Controlled Trials," *Lancet Infectious Diseases*, 2013; 13: 587-596.

12. Toh S, Reichman M, Graham D, Hampp C, Zhang R, Butler M, Iyer A, Rucker M, Pimentel M, Hamilton J, Lendle S, Fireman B; for the Mini-Sentinel Saxagliptin-AMI Surveillance Writing Group, "Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study," *Diabetes Care*, 2017; e-pub ahead of print
13. Engels E, Yanik E, Wheeler W, Gill J, Shiels M, Dubrow R, Althoff K, Silverberg M, Brooks J, Kitahata M, Goedert J, Grover S, Mayor A, Moore R, Park L, Rachlis A, Sigel K, Sterling T, Thorne J, Pfeiffer R, North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS; North American AIDS Cohort Collaboration on Research and Design of the International Epidemiologic Databases to Evaluate AIDS, "Cancer-Attributable Mortality among People with Treated Human Immunodeficiency Virus Infection in North America," *Clinical Infectious Diseases*, 2017; 65(4): 636-643.

Other Publications

1. **Horberg M**, Schatz B. [letter] Battling HIV on many fronts. *N Engl J Med*. 1998 Jan 15;338(3):198
2. **Horberg M**. Book Review: Fenway Guide to Lesbian, Gay, Bisexual and Transgender Health. *Annals Internal Medicine*, 2008; 149(5): p.368.

Abstracts and Oral Presentations

1. Rice H, Zolopa A, **Horberg M**, Klein D. Abstract 558-T, "Correlation of Phenotypic Resistance and Virologic Response to Indinavir/Ritonavir Boosted Regimens", 9th Conference of Retrovirus and Opportunistic Infections, February, 2002
2. **Horberg M**, Klein D, Luu T, Sinn K, Abstract 681, "Long Term Efficacy of Indinavir/Ritonavir in Highly ART Experienced Patients", IDSA, October, 2001 (published in *Clinical Infectious Diseases*)
3. **Horberg M**, Klein D, Luu T, Sinn K, Abstract TuPeB4442, "Durability of Nelfinavir-Based HAART," XIV International AIDS Conference, July, 2002, Barcelona
4. Rice H, Zolopa A, **Horberg M**, Klein D, Coram, M, Condra, JH, Hellmann, N, King, H, Bates, M, Abstract TuPeB4603, "Virologic Response to Ritonavir-Boosted Indinavir Regimens Correlates with Baseline Phenotypic Resistance to Indinavir," XIV International AIDS Conference, July, 2002, Barcelona, Spain
5. Szumiloski J, Wilson E, Jensen R, Campo R, Rice H, Zolopa A, **Horberg M**, Klein D, Abstract 155, "Relationship Between Phenotypic Susceptibility to Indinavir and Virologic Response to Indinavir-Ritonavir Containing Regimens Following Failure of a Previous Protease Inhibitor," 11th International HIV Drug Resistance Workshop, July, 2002, Seville, Spain
6. Klein D, Hurley L, **Horberg M**, Abstract H-1154, "Appendicitis in HIV Patients Before and After HAART," 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September, 2002.
7. Delorenze G, **Horberg M**, Karter A, Ferrara A, Quesenberry C, Tsai A, Oral Presentation 44, "Incidence and Prevalence of Diabetes Mellitus among HIV-Infected Patients in Northern California's Largest HMO," 10th Conference on Retrovirus and Opportunistic Infections, February, 2003.
8. DeWeese J, Delaney A, Klein D, **Horberg M**, Abstract 721, "Surgical Treatment of HIV Lipohypertrophy (LH) of Head and Neck (H/N)," 10th Conference on Retrovirus and Opportunistic Infections, February, 2003.

9. Szumiloski J, Wilson H, Campo R, Miller N, Rice H, Zolopa A, Klein D, **Horberg M**, Hellmann, N, Bates, M, Condra, J, Abstract 603, "Determination of an Indinavir Susceptibility Cutoff for Indinavir-Ritonavir Containing Regimens," 10th Conference on Retrovirus and Opportunistic Infections, February, 2003.
10. Fessel W, Rhee S, Hurley L, Slome S, Klein D, **Horberg M**, Flamm, J, Follansbee, S, Shafer, R, "High-Level Dual (NRTI and PI) and Triple Class Multidrug Resistance in a Large Health Maintenance Organization: Prevalence, Risk Factors, and Response to Salvage Therapy," 7th International Resistance Workshop, July, 2003.
11. **Horberg M**, Hurley L, Klein D, Follansbee S, Flamm J, Green G, Abstract 82 (oral), "Surgical Outcomes of HIV+ Patients in the Era of HAART," 11th Conference of Retrovirus and Opportunistic Infections, February, 2004.
12. Fessel W, Rhee S, Hurley L, Nguyen D, Slome S, Smith S, Klein D, **Horberg M**, Flamm J, Follansbee S, Gonzales M, Shafer R., Abstract 690, "High-Level Dual and Triple Class Multi-drug Resistance in a Large Health Maintenance Organization: Prevalence, Risk Factors, and Response to Salvage Therapy," 11th Conference on Retroviruses and Opportunistic Infections, February, 2004.
13. Hurley L, Klein D, **Horberg M**, "Exploration of Factors Contributing to Reduced CHD Risk Among a Large Cohort of HIV-1 Infected Patients," 8th International Workshop on HIV Observational Databases, March, 2004.
14. **Horberg M**, Klein D, Yu J, Sinn K, Abstract BTuPp2066, "Effect of Tenofovir on Renal Function in a "Real World" Clinic Setting," XV International AIDS Conference, July, 2004, Bangkok, Thailand.
15. Delorenze G, **Horberg M**, Karter A, Ferrara, A, Quesenberry, C, Tsai, A, Abstract 70, "Impaired Glucose Metabolism in a Large HIV+ Clinic Population," 9th International HIV Observational Database Conference, April, 2005.
16. Silverberg M, **Horberg M**, Hurley L, Klein D, Abstract MoPe15.1C07, "Demographic and Clinical Parameters Associated with HIV Quality Indicators During the HAART Era in the Largest Integrated Health Care System in California," 3rd IAS Conference on HIV Pathogenesis and Treatment, July, 2005.
17. **Horberg M**, Holodniy M, Hornberger J, Hurley L, Marrufo G, Robertus K, Deyton L, Bersoff-Matcha S, Tonwer W, Weinberg W, Antoniskis D, Mogyoros M, Dodge W, Kovach D, Abstract 760, "Comparison of the Two Largest Integrated HIV Healthcare Delivery Systems in the United States", 43rd Infectious Disease Society Of America, October, 2005.
18. Klein D, Hurley L, Quesenberry C, Silverberg M, **Horberg M**, Sidney S, Abstract 737, "Hospitalizations for CHD and MI Among Northern California HIV+ and HIV- Men: Changes in Practice and Framingham Risk Scores," 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 2006
19. Bersoff-Matcha S, Silverberg M, Hurley L, Towner W, Weinberg W, Antoniskis D, Mogyoros M, Dodge W, Dobrinich R, **Horberg M**, Abstract 887, "Differences in Response to HAART by Gender and HCV Co-infection Status in a Large HMO Setting," 13th Conference on Retroviruses and Opportunistic Infections,, Denver, CO, February 2006
20. **Horberg M**, Hurley L., Silverberg M, Hurley L, Kinsman CJ, Selby J, Oral Presentation 5, "Predictors of Improved Adherence and Disease Markers in HIV+ Patients Starting a New Regimen—A Retrospective Cohort Analysis," NIMH/IAPAC Conference on HIV Treatment Adherence, March, 2006
21. **Horberg M**, Silverberg M, Hurley L, Kinsman DJ, Abstract TuPe0107, "Impact of HIV Clinical Pharmacists on Antiretroviral Adherence and Clinical Outcomes in ARV Experienced Patients," XVI International AIDS Conference, August, 2006.

22. **Horberg M**, Silverberg M, Hurley L, Towner W, Klein D, Bersoff-Matcha S, Weinberg W, Antoniskis D, Mogyoros M, Dodge W, Dobrinich R, Kovach D, Abstract TuPe0117, “Effects of Depression and SSRI use on Adherence and HIV Clinical Outcomes in Patients Taking Combination Antiretroviral Therapy,” XVI International AIDS Conference, August, 2006.
23. Silverberg M, Leyden W, **Horberg M**, Delorenze G, Klein D, Quesenberry C, Abstract TuPe0135, “Older Age, Therapy Adherence, Comorbidities and Variable Response to antiretrovirals,” XVI International AIDS Conference, August 2006.
24. Silverberg M, Leyden W, **Horberg M**, Delorenze G, Klein D, Quesenberry C, Abstract WePe0177, “Older age associated with reduced tolerability of antiretrovirals,” XVI International AIDS Conference, August 2006.
25. Klein D, Hurley L, Silverberg M, **Horberg M**, Quesenberry C, Sidney S, Abstract 807, “Surveillance Data for Myocardial Infarction Hospitalizations among HIV+ and HIV- Northern Californians: 1994-2006,” 14th Conference on Retroviruses and Opportunistic Infections, February 2007.
26. Silverberg M, Leyden W, **Horberg M**, Hurley L, Go A, Quesenberry C, Klein D, Abstract 814, “Lipid-Lowering Therapy Responses in HIV+ and HIV- Dyslipidemic Patients Enrolled in a Large Integrated Healthcare Delivery System,” 14th Conference on Retroviruses and Opportunistic Infections, February 2007.
27. Silverberg S, Leyden W, Klein D, Quesenberry C, **Horberg M**, Abstract P-150, “Advanced Antiretroviral Treatment Failure among Kaiser Permanente Patients,” 2nd International Conference on HIV Treatment Adherence, March 2007.
28. Silverberg MJ, Leyden W, Quesenberry C, **Horberg M**, Abstract WEPEB107, “Influence of race/ethnicity on adherence to and effectiveness of antiretroviral therapy among patients with access to care,” 4th International AIDS Society Conference, Sydney, Australia, July 2007
29. **Horberg M**, Klein D, Hurley L, Silverberg M, Towner W, Antoniskis D, Kovach D, Mogyoros M, Blake W, Dobrinich R, Dodge W, Abstract WEPEB025, “Efficacy and Safety of Non-Boosted to Ritonavir-Boosted Atazanavir among Antiretroviral Naïve Patients,” 4th International AIDS Society Conference, Sydney, Australia, July 2007.
30. Fessel J, Rhee S, Klein D, Hurley L, Liu T, Follansbee S, Slome S, Flamm J, **Horberg M**, Shafer R, Abstract 892, “Low Risk of Initial ART Failure in Patients with Wild Type HIV-1 by Standard Genotypic Resistance Testing,” 15th Conference on Retroviruses and Opportunistic Infections, February 2008.
31. **Horberg M**, Tang B, Towner W, Bersoff-Matcha S, Klein D, Silverberg M, Chen W, Hurley L, Chang J, Blank J, Abstract 975, “Effect of Tenofovir on Renal Function in Patients Using HAART,” 15th Conference on Retroviruses and Opportunistic Infections, February 2008.
32. **Horberg M**, Tang B, Towner W, Bersoff-Matcha S, Klein D, Silverberg M, Chen W, Hurley L, Change J, Blank J, Oral Abstract 44, “Two Versus Three Pill HAART—Does it Make a Difference?,” 3rd IAPAC/NIMH Conference on HIV Treatment Adherence, March, 2008.
33. Mosen D, **Horberg M**, Gullion C, Meenan R, Roblin D, Oral Abstract THPDB105, “Effect of Fixed-Dosed Combination Therapies on HAART Initiation among an ARV Naïve Population in a Managed Care Setting,” XVII International AIDS Conference, August, 2008.
34. Meenan R, O’Keeffe-Rosetti M, Kimes T, Leyden W, Antoniskis D, Saget B, Young T, **Horberg M**, Abstract TUPE0236, “Excess Prevalence-based costs of multiple HAART regimens among HIV-infected patients in a US health maintenance organization,” XVII International AIDS Conference, August, 2008.

35. Towner W, Klein D, Follansbee S, Yu K, Kerrigan H-L, **Horberg M**, Abstract TUPE0115, "Pilot Study of Switching Enfuvirtide to Raltegravir in HIV-1 Positive Patients Well Controlled on an Enfuvirtide Based Regimen," XVII International AIDS Conference, August, 2008.
36. **Horberg M**, Ranatunga D, Silverberg M, Klein D, Abstract L-648, "Syphilis in Northern California," 48th ICAAC/46th IDSA Meeting, October, 2008.
37. Silverberg M, Leyden W, Chao C, Xu L, Tang B, **Horberg M**, Klein D, Towner W, Abrams D, Oral Abstract 30, "Infection-related Non-AIDS-Defining Cancer Risk in HIV-Infected and –Uninfected Persons," 16th Conference on Retroviruses and Opportunistic Infections, February, 2009.
38. Hurley L, Leyden W, Xu L, Silverberg M, Chao C, Tang B, Towner W, **Horberg M**, Klein D, Abstract 710, "Updated Surveillance of Cardiovascular Event Rates among HIV-infected and HIV-uninfected Californians, 1996 to 2008," 16th Conference on Retroviruses and Opportunistic Infections, February, 2009.
39. Chao C, Xu L, Abrams D, Tang B, Leyden W, **Horberg M**, Towner W, Klein D, Silverberg M, Abstract 871, "Prognosis of Non-Hodgkin's Lymphoma in HIV-Infected Patients," 16th Conference on Retroviruses and Opportunistic Infections, February, 2009.
40. Rhee SY, Fessel W, Klein D, Hurley L, Flamm J, Follansbee S, **Horberg M**, Shafer R., "Virologic Outcome Associated with Genotype-Guided Therapy in Patients with Transmitted HIV-1 Drug Resistance (TDR) Between 2003 and 2006," XVIII International HIV Drug Resistance Workshop, June, 2009.
41. **Horberg M**, Hurley L, Towner W, Gambatese R, Klein D, Antoniskis D, Weinberg W, Quesenberry C, Johnson M, Silverberg M, Abstract CDB125, "Antiretroviral Adherence and Achieving Maximal Viral Control by Regimen Class," 5th IAS Conference, Cape Town, SA, July 2009.
42. Tran T, Ray G, Saddier P, **Horberg M**, Yawn B, Li Y, Castillo A, Silverberg M, Quesenberry C, Habel L, "Incidence and Risk Factors of Herpes Zoster in Cancer Patients," 47th Annual Meeting of the Infectious Disease Society of America, Philadelphia, 2009.
43. Blanco J, Rhee S, **Horberg M**, Follansbee S, Hurley L, Liu T, Klein D, Fessel W, Shafer R, "Virologic Response to Raltegravir Salvage and Maintenance Therapy," 47th Annual Meeting of the Infectious Disease Society of America, Philadelphia, 2009.
44. **Horberg M**, Postlethwaite D, Hung Y-Y, Hurley L, Sinclair F, Lantzman E, Schwarz E, Armstrong MA, Abstract 932, "Use of Contraception among HIV-Infected Women of Reproductive Age in Northern California," 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010.
45. Althoff K, Gange S, Klein M, **Horberg M**, Bosch R, Hogg R, Zhang J, Moore R on behalf of NA-ACCORD, Abstract 982, "Late Presentation for HIV Care in the US and Canada," 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010.
46. Silverberg S, Xiu L, Chao C, Leyden W, **Horberg M**, Klein D, Towner W, Quesenberry C, Neugebauer R, Abrams D, Oral Abstract 28, "Immunodeficiency, HIV RNA Levels, and Risk of Non-AIDS Defining Cancers," 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010.
47. Lo J, Hurley L, Go A, Klein D, **Horberg M**, Lee G, Quesenberry C, Silverberg M, Abstract 715, "Impact of HIV Infection on Outcomes Following Coronary Revascularization," 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2010.
48. Golub E, Deeks S, Hunt P, Martin J, Zhang J, **Horberg M**, Gebo K, Kitahata M, Rachlis A, Greenblatt R, Saag M, Kirk G, Sterling T, Napravnik S, Moore R, Gange S, for the NA-ACCORD, "Prevalence of

extreme virologic and immunologic control in North American HIV treatment sites,” 2010 International Workshop on HIV Observational Databases (IWHOD), Sitges, Spain, 2010.

49. Armstrong, MA, Postlethwaite D, Hung YY, **Horberg M**, Sinclair F, Lantzman E, Schwarz EB. “Use of Contraception by Women with Chronic Medical Conditions,” 18th Annual Congress of American Medical Women’s Association, Washington, DC, 2010.
50. **Horberg M**, Chao C, Hurley L, Tang B, Quesenberry C, Towner W, Silverberg M, “Prescription of a New Class of Antiretroviral Medication (ARV) in a Large Integrated Healthcare System,” NIMH/IAPAC Treatment Adherence Conference, Miami, 2010 (Poster)
51. **Horberg M**, Hurley L, Towner W, Gambatese R, Klein D, Antoniskis A, Weinberg W, Kadlecik P, Remmers C, Dobrinich R, Quesenberry C, Johnson M, Silverberg M, “Antiretroviral Adherence and HIV RNA Control Quality Measurement,” NIMH/IAPAC Treatment Adherence Conference, Miami, 2010 (Oral Abstract)
52. Towner W., Xu L., Silverberg M., Leyden W., Chao C., Klein D., Hurley L., Quesenberry C., **Horberg M**, Abstract TUAB0102, "Fatal and Non-fatal in HIV-infected versus HIV-uninfected Persons Enrolled in Kaiser Permanente California, A Large Managed Care Organization," XVIII International AIDS Conference, Vienna, Austria, July, 2010 (Oral Abstract).
53. Althoff K, Gebo K, Gange S, Klein M, Brooks J, Hogg R, Bosch R, **Horberg M**, Saag M, Kitahata M, Eron J, Napravnik S, Rourke S, Gill MJ, Rodriguez B, Sterling T, Deeks S, Martin J, Jacobson L, Kirk G, Collier A, Benson C, Silverberg M, Goeder J, McKaig R, Thorne J, Rachlis A, Moore R, Justice A for the NA-ACCORD of IeDEA, “CD4 Count at Presentation for HIV Care in the United States and Canada: Are those Over 50 Years More Likely to have a Delayed Presentation,” International Workshop on HIV and Ageing, 2010
54. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, Abstract 1131, “Impact of Provider Experience Characteristics on HIV-Related Outcomes among cART Naive,” Infectious Disease Society of America 48th Annual Meeting, Vancouver, Canada, October, 2010
55. Silverberg M, Klein D, Leyden W, Chao C, **Horberg M**, Towner W, Quesenberry C, Neugebauer R, Abrams D, Van Den Eeden S, Abstract 1097, “Prostate Cancer Risk and Use of Prostate Specific Antigen Tests among HIV-infected and HIV-uninfected Men,” Infectious Disease Society of America 48th Annual Meeting, Vancouver, Canada, October, 2010
56. Silverberg M, Leyden W, L, Chun C, **Horberg M**, Klein D, Towner W, Quesenberry C, Neugebauer R, Abrams A, Oral Abstract 81, “Antiretroviral therapy use and risk of cancer in HIV patients,” 18th Conference on Retroviruses and Opportunistic Infections, February, 2011 (Oral Presentation)
57. Klein D, Leyden W, Xu L, Chao C, **Horberg M**, Towner W, Hurley L, Quesenberry C, Silverberg M. “Contribution of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members,” 18th Conference on Retroviruses and Opportunistic Infections, February, 2011 (Oral Poster)
58. Justice A, Modur S, Tate J, Althoff K, Gange S, Jacobson L, Gebo K, Kitahata M, **Horberg M**, Napravnik S for the NA-ACCORD of IeDEA, “A Prognostic Index for those Aging with HIV: Extension of the VACS Index to those on Combination Antiretroviral Therapy,” 18th Conference on Retroviruses and Opportunistic Infections, February, 2011
59. Althoff K, Rebeiro P, Gill MJ, **Horberg M**, Eron J, Napravnik S, Anastos K, Bosch R, Moore R, Gange S, for NA-ACCORD of IeDEA, “Trends in HIV Viral Load among Adults in Clinical Care in the US and Canada, 1997-2007,” 18th Conference on Retroviruses and Opportunistic Infections, February, 2011

60. Chao C, Xu L, Abrams D, Towner W, **Horberg M**, Leyden, Silverberg M, Abstract 869, "Statin Use and Risk of Non-Hodgkin's Lymphoma in HIV-infected Persons," 18th Conference on Retroviruses and Opportunistic Infections, Boston, Massachusetts, February 2011
61. Althoff K, Gange S, Klein M, Brooks J, Hogg R, Bosch R, **Horberg M**, Saag M, Moore R, for the NA-ACCORD, "Characteristics of Late Presenters and Timing of Antiretroviral Therapy Initiation," 15th International Workshop on HIV Observational Databases, Prague, Czech Republic, March, 2011
62. Rebeiro P, Althoff K, Gill MJ, Brooks J, Buchacz K, Gebo K, Martin J, **Horberg M**, Hogg R, Thorne J, Klein M, Sterling T, Moore R, Gange S, for the NA-ACCORD, Abstract 15_132, "Sustained Care after Presentation among HIV-Infected Adults in North America: The Importance of Churn in Observational Cohorts," 15th International Workshop on HIV Observational Databases, Prague, Czech Republic, March, 2011
63. Meenan R, **Horberg M**, Silverberg M, Chao C, Williams A, Keast E, Leyden W, Xu L, Tang B, Antoniskis D, Towner W, Abstract C-A5-01, "Development of Prevention Index Methodology for Application to HIV Quality of Care," 17th Annual HMO Research Network Conference, Boston, MA, March, 2011
64. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, "Determination of Optimized Multidisciplinary Care Teams for Maximal Antiretroviral Therapy Adherence," 6th International Conference on HIV Treatment and Prevention Adherence, Miami, FL, May, 2011 (Oral presentation)
65. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, Abstract MOPE464, "Impact of Provider Characteristics on HIV-related Outcomes among Antiretroviral Experienced Patients," The 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July, 2011
66. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, Abstract MOPE422, "Determination of Optimal Multidisciplinary Care Teams (MDCT) for Achieving HIV RNA Below Limits of Quantification (BLQ)," The 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July, 2011
67. Gomez V, Somkin, C, Potter M, Ackerson L, Dao T, **Horberg M**, Walsh J, "Development, Implementation, and Dissemination of the FLU-FIT Program in Kaiser Permanente Northern California," APHA 139th Annual Meeting, Washington, DC, October, 2011
68. **Horberg M**, Hurley L, Towner, W, Gambatese R, Klein D, Antoniskis D, Weinberg W, Kadlecik P, Kovach D, Mogyoros M, Remmers C, Quesenberry C, Silverberg M, Johnson M, Abstract 484, "HIV Quality Metrics: Association between Retention in Care and Maximal Viral Control," 49th Annual Meeting of the Infectious Diseases Society of America, October, 2011
69. Towner W, Leyden W, Chao C, Xu L, **Horberg M**, Klein D, Tang B, Hurley L, Silverberg M, Oral abstract 1393, "Rhabdomyolysis in HIV-infected versus HIV-uninfected Persons Enrolled in Kaiser Permanente California," 41st Annual Meeting of the Infectious Disease Society of America, Boston, Massachusetts, October 2011
70. **Horberg M**, Hurley L, Klein D, Silverberg M, Quesenberry C, Mugavero M, Abstract 1129, "Early Missed Office Visits Post-HIV Diagnosis and Mortality in a Large Healthcare System," 19th Conference on Retroviruses and Opportunistic Infections, March, 2012
71. Hanna D, Gebo K, Hessol N, **Horberg M**, Kirk G, Kitahata M, Napravnik S, Sterling T, Willig J, and Gange S for the NA-ACCORD of IeDEA, "Disparities in Rates of HIV treatment Initiation and Viral Load Suppression across US States, 2001-2007," 19th Conference on Retroviruses and Opportunistic Infections, March, 2012

72. Silverberg M, Chao C, Leyden W, Xu L, Yu J, **Horberg M**, Klein D, Towner W, Quesenberry C, Abrams D, "Cancer Stage, Age at Diagnosis and Survival Comparing HIV+ and HIV- Individuals with Common Non-AIDS-Defining Cancers," 19th Conference on Retroviruses and Opportunistic Infections, March, 2012
73. Delorenze G, **Horberg M**, Silverberg M, Tsai A-L, Quesenberry C, "Time Trends in Methicillin-resistant staphylococcus aureus (MRSA) Infection Rates Comparing HIV-infected Patients with the General (HIV-uninfected) Patient Population," 19th Conference on Retroviruses and Opportunistic Infections, March, 2012
74. Justice A, Modur S, Tate J, Althoff K, Gange S, Jacobson L, Gebo K, Kitahata M, **Horberg M**, Napravnik S for the NA-ACCORD of IeDEA, "A Prognostic Index for those Aging with HIV: Extension of the VACS Index to Those on Combination Antiretroviral Therapy," 19th Conference on Retroviruses and Opportunistic Infections, March, 2012
75. Hanna DB, Gebo KA, Hessol NA, **Horberg M**, Kirk GD, Kitahata MM, Napravnik S, Sterling TR, Willig JH, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA, "Disparities in Rates of HIV Treatment Initiation and Viral Load Suppression across U.S. States, 2001-2007," 19th Conference on Retroviruses and Opportunistic Infections, March, 2012
76. Althoff K, Rebeiro P, Gill MJ, **Horberg M**, Eron J, Napravnik S, Anastos K, Bosch R, Moore R, Gange S for the NA-ACCORD of IeDEA, "Trends in HIV Viral Load among Adults in Clinical Care in the US and Canada, 1997-2007," 19th Conference on Retroviruses and Opportunistic Infections, March, 2012
77. Klein D, Leyden W, Xu L, Chao C, **Horberg M**, Towner W, Hurley L, Quesenberry C, Silverberg M, Abstract 060, "Contribution of Immunodeficiency to Coronary Heart Disease: Cohort Study of HIV-infected and HIV-uninfected Kaiser Permanente Members," Epidemiology and Prevention/Nutrition, Physical Activity, and Metabolism 2012 Scientific Sessions, San Diego, CA, March, 2012
78. Silverberg M, Leyden W, Stewart C, Ralston J, **Horberg M**, Carzasty S, Grothaus L, Catz S, "Change in Adherence to Antiretrovirals After Initial Use of an Electronic Share Medical Record among HIV-Infected Individuals," HMO Research Network Conference, Seattle, WA, April, 2012
79. Rebeiro PF, Althoff KN, Gill MJ, Krentz H, Gebo KA, **Horberg M**, Hogg RS, Thorne JE, Sterling TR, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, "Factors Associated with Absence from HIV Clinical Care Among Black Patients in the NA-ACCORD: Application of Beta-binomial and Transition Models to Observational Cohort Data," 2012 International Workshop on HIV Observational Databases (IWHOD), Athens, Greece, May, 2012.
80. **Horberg M**, Hurley L, Towner W, Allerton M, Tang B, Catz S, Silverberg M, Quesenberry C, "Impact on Emergency Department (ED) and Hospitalization Utilization among Optimized Multidisciplinary Care Teams Associated with Maximal Antiretroviral Adherence," 7th International Conference on Treatment and Prevention Adherence, Miami Beach, FL, June, 2012
81. Catz S, Amico KR, Balderson B, Hogan P, **Horberg M**, Mahoney C, McClure J, Silverberg M, Ralston J, "Individually Tailoring a Health Information Technology Adherence Intervention Using Patient-Reported Web Survey Responses," 7th International Conference on Treatment and Prevention Adherence, Miami Beach, FL, June, 2012
82. Rebeiro P, Althoff K, Gill J, Krentz H, Gebo K, Martin J, **Horberg M**, Hogg R, Thorne J, Klein M, Sterling T, Moore R, Gange S for the NA-ACCORD of IeDEA, "Modeling Clinical Retention in the North American HIV Population," 2012 Society for Epidemiologic Research, Minneapolis, MN, June, 2012

83. Meenan R, **Horberg M**, Silverberg M, Chao C, Williams A, Vogt T, Antoniskis D, Towner W, Keast E, Leyden W, Xu L, Vijayadeva V, “Developing New Quality Measures for HIV Care Using the Electronic Medical Record,” XIX International AIDS Conference, Washington, DC, July, 2012
84. Hanna D, Buchacz K, Hessol N, **Horberg M**, Jacobson L, Kitahata M, Moore R, Napravnik S, Patel P, Gebo K, Willig J, Sterling T, Kirk G, Collier A, Ohl M, Thorne J, Gange S for the NA-ACCORD of IeDEA, “Association between State AIDS Drug Assistance Program Features and Treatment Initiation in Clinically Eligible US HIV-Infected Persons,” XIX International AIDS Conference, Washington, DC, July, 2012
85. Rebeiro P, Althoff K, Gill J, Krentz H, Gebo K, Martin J, **Horberg M**, Hogg R, Thorne J, Klein M, Rourke S, Sterling T, Moore R, Gange S for the NA-ACCORD of IeDEA, “Patterns and Predictors of Absences from HIV Care in North America (2000-2008),” XIX International AIDS Conference, Washington, DC, July, 2012
86. Abraham A, Lau B, Estrella M, Szczech L, Rourke S, Rodriguez B, Rachlis A, Chirag P, Napravnik S, Moore R, Klein M, Kitahata M, Jing J, **Horberg M**, Harris M, Eron J, Crane H, Bosch R, Benson C, Anastos K, Althoff K, Lucas G, for the NA-ACCORD of IeDEA, “Tenofovir-Associated Kidney Function decline with a PI-based Versus NNRTI-based Regimen,” XIX International AIDS Conference, Washington, DC, July, 2012
87. Althoff K, Buchacz K, Hall I, Zhang J, Hanna D, Rebeiro P, Gange S, Moore R, Kitahata M, Gebo K, Martin J, Justice A, **Horberg M**, Hogg R, Sterling T, Cescon A, Klein M, Thorne J, Crane H, Mugavero M, Napravnik S, Kirk G, Jacobson L, Rodriguez B, Brooks J for the NA-ACCORD of IeDEA, “Trends in Antiretroviral Therapy Use, HIV RNA Plasma Viral Load, and CD4 T-Lymphocyte Counts at Death among HIV-Infected Persons in Care in the United States, 2000-2008, XIX International AIDS Conference, Washington, DC, July, 2012
88. Hanna D, Buchacz K, Hessol N, **Horberg M**, Jacobson L, Kitahata M, Moore R, Napravnik S, Patel P, Gebo K, Willig J, Sterling T, Kirk G, Collier A, Ohl M, Thorne J, Gange S for the NA-ACCORD of IeDEA, “Trends in Antiretroviral Therapy Initiation and Virologic Suppression among Newly Clinically-Eligible HIV-Infected Individuals in North America, 2001-2009,” XIX International AIDS Conference, Washington, DC, July, 2012
89. **Horberg M**, Hurley L, Towner W, Gambatese R, Klein D, Antoniskis D, Kadlecik P, Kovach D, Remmers C, Silverberg M, Abstract 1033, “HIV Spectrum of Engagement Cascade in a Large Integrated Care System by Gender, Age, and Methodologies,” 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, March 2013
90. Althoff K, Rebeiro P, **Horberg M**, Buchacz K, Gebo K, Sterling T, Kitahata M, Justice A, Moore R, for the North American AIDS Cohort Collaboration on Research and Design, Abstract 1026, “Application of Indicators to Monitor US Department of Health and Human Services-Funded HIV Services in the NA-ACCORD,” 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, March, 2013
91. Rebeiro P, **Horberg M**, Gebo K, Brooks J, Buchacz K, Silverberg M, Gill MJ, Moore R, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Abstract 1035, “No meaningful difference between retention indicators from US government agencies within the largest HIV Cohort Collaboration in North America,” 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, March, 2013
92. Althoff K, Abraham A, Estrella M, Crane H, Freeman A, Gill J, Golub E, **Horberg M**, Jacobson L, Kitahata M, McKaig R, Palella F, Parikh C, Moore R, Jing Y, Rodriguez B, Eron J, Napravnik S, Buchacz K, Silverberg M, Mayor A, Krishnasami Z, Lucas G, for the NA-ACCORD of IeDEA, “Incidence of End Stage Renal Disease in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD),” 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia, July, 2013

93. Silverberg M, Leyden W, Stewart C, Ralston J, **Horberg M**, Grothaus L, Catz S, "Antiretroviral therapy adherence and use of an electronic shared medical record among HIV-positive Individuals," 46th Annual Society for Epidemiologic Research Meeting, Boston, MA, June, 2013
94. Althoff K, Rebeiro P, Hanna D, Hogg R, Brooks J, Abraham A, **Horberg M**, Buchacz K, Gil MJ, Mayor A, Thorne J, Sterling T, Williams C, Rachlis A, Burchell A, for the North American AIDS Cohort Collaboration on Research and Design, "Measures on the Map: A Geographical Display of HIV Infection and Care Indicators," 17th International Workshop on HIV Observational Databases, Cavtat, Croatia, April, 2013
95. Silverberg M, Hurley L, Prasad A, Zaroff J, Klein D, **Horberg M**, Go A, Lo J, Abstract 75, "Mortality Following Hospitalization for Acute Coronary Syndrome among HIV+ and HIV- Patients," 43rd Annual Meeting of the Infectious Disease Society of America, San Francisco, California, October, 2013
96. Silverberg M, Hurley L, Prasad A, Zaroff J, Klein D, **Horberg M**, Go A, Lo J, "Similar outcomes for HIV+ and HIV- patients within three years following hospitalization for acute coronary syndrome," *American Heart Association Annual Meeting*, October, 2013, Washington, DC
97. Marcus J, Leyden W, Chao C, Chow F, **Horberg M**, Hurley L, Klein D, Quesenberry C, Towner W, Silverberg M, "HIV Infection and Immunodeficiency as Risk Factors for Ischemic Stroke," 21st Conference on Retroviruses and Opportunistic Infections, Boston, MA, March, 2014
98. Maeda J, Lee K, **Horberg M**, "Comparative Health Systems Research among Integrated Delivery Systems and Managed Care Organizations: A Systematic Review," HMO Research Network Conference, Phoenix, AZ, April, 2014
99. Yehia B, Rebeiro P, Althoff K, Gange S, Samji H, **Horberg M**, Napravnik S, Gebo K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Age Impacts the Association of Retention in Care and Viral Suppression," 21st Conference on Retroviruses and Opportunistic Infections, Boston, MA, March, 2014
100. Klein D, Leyden W, Chao C, **Horberg M**, Towner W, Hurley L, Quesenberry C, Silverberg M, "No Difference in Incidence of Myocardial Infarction for HIV+ and HIV- Individuals in Recent Years," 21st Conference on Retroviruses and Opportunistic Infections, Boston, MA, March, 2014 (Accepted)
101. Rebeiro PF, Althoff KN, Lau B, **Horberg M**, Mugavero MJ, Samji H, Napravnik S, Silverberg MJ, Rachlis A, and Gange SJ for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the IeDEA, "Labs are Imperfect Proxies of Encounters: Retention Trends in the Largest North American HIV Cohort," 18th International Workshop on HIV Observational Databases (IWHOD), Sitges, Spain, March, 2014
102. Rebeiro P, Gange S, **Horberg M**, Abraham A, Napravnik S, Samji H, Yehia B, Curriero F, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "The geography of HIV clinical retention in the United States: regional trends in the NA-ACCORD," 18th International Workshop on HIV Observational Databases (IWHOD), Sitges, Spain, March, 2014
103. **Horberg M**, Hurley L, Klein D, Towner W, Kadlecik P, Finnegan C, Mogyoros M, Matyas RJ, Brachman P, Silverberg M, "Methodology Issues in HIV Quality Performance Measures," XX International AIDS Conference, Melbourne Australia, July, 2014
104. **Horberg M**, Hurley L, Klein D, Towner W, Kadlecik P, Finnegan C, Mogyoros M, Matyas RJ, Brachman P, Silverberg M, "The HIV Care Cascade Measured Over Multiple Time Periods Varies by Time Period and Method," XX International AIDS Conference, Melbourne Australia, July, 2014 (Accepted as Oral Abstract)

105. Silverberg M, Muthulingam D, Leyden W, Yee A, Marcus J, **Horberg M**, Klein D, Towner W, Chao C, Baxter R, "Incidence and Risk Factors of Invasive Pneumococcal Disease Among HIV-positive and HIV-negative Adults," XX International AIDS Conference, Melbourne Australia, July, 2014
106. **Horberg M**, Hurley L, Klein D, Towner W, Kadlecik P, Finnegan C, Mogyoros M, Matyas R, Brachman P, Blank J, Ellis C, Silverberg M, Abstract 88, "The HIV Care Cascade Measured over Multiple Time Periods Varies by Age and Gender," IDWeek 2014 (Annual Meeting of IDSA/HIVMA/SHEA/PIDS), Philadelphia, PA, October, 2014 (Accepted as Oral Abstract)
107. Goddard K, Cardoza N, Croen L, Feigelson H, Harris K, Honda S, **Horberg M**, Jonas C, Koebnick C, Nguyen M, Owen-Smith A, Rowell S, Schaefer C, Smith KS, Somkin C, Vu J, Wrenn M, Yonehara C, Emmons K, "The Kaiser Permanente Biobank: A Multi-Region, Multi-Ethnic Resource Linking Specimens and Electronic Medical Records for Broad Research in an Integrated Health Care Delivery System," American Society of Human Genetics Annual Meeting, San Diego, California, October, 2014
108. Gold R, Esterberg E, Hollombe C, Vakarcs T, Arkind J, Tran M, Burdick T, Faer M, Johnson M, **Horberg M**, "Guideline-discordant imaging for low back pain in primary care: A cross-system analysis," NAPCRG annual conference, New York, NY , November 21-25 2014
109. Marcus J, Leyden W, Chao C, Xu L, Quesenberry C, Klein D, Towner W, **Horberg M**, Silverberg M, "Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status," 2nd Conference on Overcoming Health Disparities in the Bay Area: Focus on HIV and HCV, San Francisco, CA, 2015
110. Rebeiro P, Yehia B, Gebo K, Lau B, Mayer K, **Horberg M**, Kitahata M, Gill J, Sterling T, Gange S, "Continuous Retention Predicts Viral Suppression Across the US and Canada," 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015
111. Wong C, Gange S, **Horberg M**, Kirk G, Rachlis A, Gill J, Thorne J, Hogg R, Goedert J, Althoff K, "Age-Related Morbidities Among HIV-Infected Adults from 2000-2010," 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015
112. Calikins K, Eron J, Abraham A, Buchacz K, **Horberg M**, Tate J, Napravnik S, Moore R, Bosch R, Lau B, "CD4 Reconstitution is Related to CD4 at Effective Antiretroviral Initiation," 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2015
113. Feigelson H, Croen L, Goddard K, Honda S, **Horberg M**, Koebnick C, Owne-Smith A, Rowell S, Schaefer C, Somkin C, Emmons K, "The Kaiser Permanente Biobank: A Multi-Region Resource Linking Specimens and Electronic Medical Records for Broad Research in an Integrated Health Care Delivery System," HMO Research Network Conference, Long Beach, CA, 2015
114. Marcus J, Leyden W, Neugebauer R, Chao C, Xu L, Quesenberry C, Klein D, Towner W, **Horberg M**, Silverberg M, "Use of Abacavir and Risk of Cardiovascular Disease among HIV-Infected Individuals: A Marginal Structural Model Approach," Society for Epidemiological Research Annual Meeting, 2015
115. Rebeiro P, Abraham A, **Horberg M**, Gill J, Yehia B, Silverberg M, Rachlis A, Samji H, Sterling T, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Racial Differences in Discontinuity and Re-Entry into HIV Care after Antiretroviral Therapy Initiation in the U.S. and Canada," 2015 International Workshop on HIV Observational Databases," Sitges Spain, 2015
116. Abraham A, Althoff K, Jing Y, Estrella M, Wang R, Wester W, Kitahata M, Bosch R, Crane H, Eron J, Gill MJ, **Horberg M**, Justice A, Klein M, Mayor A, Moore R, Palella F, Parikh C, Silverberg M, Golub E, Jacobson L, Napravnik S, Lucas G, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Use of Tenofovir in HIV-Infected Patients at Risk for End Stage Renal Disease," 2015 International Workshop on HIV Observational Databases," Sitges Spain, 2015

117. Althoff K, Jing Y, Gebo K, Klein M, Kitahata M, Gill J, Dubrow R, Silverberg J, Samji H, Wong C, Rachlis A, **Horberg M**, Lau B, Moore R, Gange S, Lucas G, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Aging Better with HIV: Using the Population Attributable Fraction to Inform Interventions to Reduce End-Stage Renal Disease in HIV+ Adults," 2015 International Workshop on HIV Observational Databases, Sitges Spain, 2015
118. **Horberg M**, Hurley L, Klein D, Towner W, Kadlecik P, Remmers C, Gambatese R, Blank J, Ellis C, Silverberg M, "The HIV Care Cascade Measured Over Multiple Time Periods Varies by Race and Ethnicity," NIMH/IAPAC Treatment Adherence Conference, Miami, FL, 2015 (Oral Abstract)
119. Johnson A, Kirk G, Drummond B, O'Cleirigh C, Hogg R, Brooks J, Moore R, **Horberg M**, Rourke S, Mayor A, Gill MJ, Martin J, Napravnik S, Eron J, Kitahata M for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Cigarette Smoking and the Relationship with Retention in HIV Care, 2008-2010," Society for Research on Nicotine and Tobacco Annual Meeting, Philadelphia, PA, 2015
120. Calkins K, Eron J, Abraham A, Buchacz K, **Horberg M**, Tate J, Napravnik S, Moore R, Bosch R, Lau B, "CD4 Reconstitution is related to CD4 at Effective Antiretroviral Treatment Initiation," 8th IAS Conference on HIV Pathogenesis, Treatment, and Prevention, Vancouver, BC, July, 2015
121. **Horberg M**, Blank J, Rubenstein K, Hurley L, Marcus J, Klein D, Kadlecik P, Silverberg M, Abstract 1035, "Differences in Viral Suppression by Frequency and Type of Healthcare Visits," 23rd Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2016
122. Marcus J, Chao C, Leyden W, Xu L, Quesenberry C, Klein D, Towner W, **Horberg M**, Silverberg M, "Narrowing the Gap in Life Expectancy for HIV+ Compared with HIV- Individuals," 23rd Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2016 (Oral Abstract)
123. Rebeiro P, Mugavero M, **Horberg M**, Mayer K, Martin J, Kitahata M, Abraham A, Moore R, Sterling T, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Regional Differences in Ancillary Care Services for HIV-Infected Adults in the US: Policy Implications," 20th International Workshop on HIV Observational Databases, Budapest, Hungary, April, 2016
124. Rebeiro P, Althoff K, Lau B, Gill J, Abraham A, **Horberg M**, Kitahata M, Yehia B, Samji H, Brooks J, Buchacz K, Napravnik S, Silverberg M, Rachlis A, Gebo K, Sterling T, Moore R, Gange S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Laboratory Measures are Imperfect Proxies of Primary Care Encounters: Implications for Quantifying Clinical Retention among HIV-Infected Adults in North America," 23rd Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2016
125. Althoff K, Kucirka L, Abraham A, Massie A, Kitahata M, **Horberg M**, Fischer M, Silverberg M, Butt A, Boswell S, Martin J, Durand C, Locke J, Moore R, Lucas G, "The Racial Survival Paradox in HIV+ End-stage Renal Disease (ESRD) Patients," 23rd Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2016
126. Wang R, Althoff K, Kucirka L, Abraham A, Massie A, Kitahata M, **Horberg M**, Fischer M, Silverberg M, Butt A, Boswell S, Martin J, Durand C, Locke J, Moore R, Lucas G, "Short-term Renal Impact of tenofovir among HIV-infected Patients in North America," 23rd Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2016
127. Desir FA, Rebeiro PF, Moore RD, Crane HM, Gabler K, Margolick JB, Bosch R, **Horberg M**, Silverberg MJ, and Althoff KN. Retention, ART use, and viral suppression among women linked to HIV care in the United States," 2017 Conference on Retroviruses and Opportunistic Infections (CROI), 2017, Seattle, Washington (Oral)

128. Desir F, Rebeiro P, Moore R, Crane H, Gabler K, Margolick J, Bosch R, **Horberg M**, Silverberg M, Althoff K, Abstract 1002, "Retention, ART Use, and Viral Suppression among Young Adults Newly Linked to HIV Care," 2017 Conference on Retroviruses and Opportunistic Infections (CROI), 2017, Seattle, Washington
129. Althoff K, **Horberg M**, Eron J, Gange S, Crane H, Justice A, Kitahata M, Margolick J, Eyawo O, Moore R, Abstract 2096, "The Large Gap between Statin Eligibility and Prescription among HIV+ in North America," 2017 Conference on Retroviruses and Opportunistic Infections (CROI), 2017, Seattle, Washington
130. Althoff K, Palella F, Gebo K, Gange S, Rabkin C, Thorne J, **Horberg M**, Klein D, Kitahata M, Moore R, Abstract 2022, "Impact of Smoking, Hypertension & Cholesterol on Myocardial Infarction in HIV+ Adults," 2017 Conference on Retroviruses and Opportunistic Infections (CROI), 2017, Seattle, Washington
131. Sun J, Althoff KN, Jing Y, **Horberg M**, Buchacz K, Gill MJ, Justice AC, Rabkin C, Goedert JJ, Thorne J, Mayor A, Crane HM, Kitahata MM, Klein MB, Kirk GD, "Risk of hepatocellular carcinoma among persons living with HIV and viral hepatitis co-infection in the United States and Canada, 1996-2009," 2017 International Workshop on HIV Observational Databases, Lisbon, Portugal, April, 2017 (Oral)
132. Althoff KN, Wong C, Hogan B, Desir F, Zhang J, Modur S, You B, Liu B, Jing Y, **Horberg M**, Rebeiro PF, Justice AC, Kitahata MM, Gange SJ. "Using observation windows for improving ascertainment assumptions in clinical cohort studies: Illustration of ascertaining diabetes outcomes.," 2017 International Workshop on HIV Observational Databases, Lisbon, Portugal, April, 2017
133. Tartof S, Arduino J, Wei R, Hsu J-W, Rubenstein K, Hu H, **Horberg M**, Derose S, Rodriguez C, "The Additional Impact of Chronic Kidney Disease on Cardiovascular Outcomes and Death among HCV Patients," EASL The International Liver Congress, Barcelona, Spain, April, 2016
134. Tartof S, Arduino J, Wei R, Hsu J-W, Rubenstein K, Hu H, **Horberg M**, Derose S, Rodriguez C, "The Additional Impact of Hepatitis C Infection on Cardiovascular Outcomes and Death among Patients with Chronic Kidney Disease," Digestive Disease Week, San Diego, California, 2016
135. Desir F, Rebeiro P, Moore R, Crane H, Gabler K, Margolick J, Bosch R, **Horberg M**, Silverberg M, Althoff K, "Retention, ART Use, and Viral Suppression among Women Linked to HIV Care in the United States," CFAR 2016 Joint Symposium on HIV Research in Women, Washington, DC, 2016
136. **Horberg M**, Blank J, Rubenstein K, Kadlecik P, Hurley L, Silverberg M, "Changes in Antiretroviral Therapy (ART) and Maximal Viral Suppression over Time by Age, Gender, Race/Ethnicity, and HIV Risk among HIV-Infected Patients in an Integrated Health System in the United States," 9th IAS Conference on HIV Science (IAS 2017), Paris France, July, 2017
137. **Horberg M**, Blank J, Rubenstein K, Hurley L, Kadlecik P, Klein D, Silverberg M, "Do HIV Viral Suppression Rates Vary by Frequency and Type of Healthcare Visits in an Integrated Health System," 12th International Conference on HIV Treatment and Prevention Adherence (Adherence 2017), Miami, Florida, June 2017
138. Althoff K, Moore R, Gill J, **Horberg M**, Justice A, Kitahata M, Klein M, Desir F, Mathews W, Mayor A, Rebeiro P, Silverberg M, Gange S, Hogg R, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Life Expectancy in Key Populations of Adults with HIV in the US and Canada," CROI 2018, Boston MA (Accepted)
139. Benson E-M, Klein M, Kitahata M, Moore R, Lo Re V, **Horberg M**, Mayor A, Silverberg M, Kim N, Eron J, Cachay E, Hull M, Gange S, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Survival after End-Stage Liver Disease in Adults with HIV: Findings from the NA-ACCORD," CROI 2018, Boston MA (Accepted)

140. Lo Re V, Newcomb C, Carbonari D, Roy J, Kitahata M, Lim J, Silverberg M, Mayor A, **Horberg M**, Cachay E, Hull M, Moore R, Klein M, Kim HN, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Determinants of Liver Complications among HIV/Hepatitis B-Coinfected Patients,” CROI 2018, Boston MA (Accepted)
141. Desir F, Lesko C, Moore R, **Horberg M**, Rebeiro P, Gill J, Kitahata M, Silverberg M, Levison J, Klein M, Mayor A, Justice A, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Trends in Unsuppressed HIV RNA after Linkage to Care among Key Populations,” CROI 2018, Boston MA (Accepted)
142. Desir F, Lesko C, Moore R, Silverberg M, Rebeiro P, **Horberg M**, Kitahata M, Crystal S, Mayor A, Klein M, Justice A, Gill J, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Age-Dependent Racial/Ethnic Disparities in Longitudinal HIV Care Indicators,” CROI 2018, Boston MA (Accepted)
143. Althoff K, Buchacz K, Moore R, Gange S, Kitahata M, **Horberg M**, Bosch R, Lee J, Martin J, Mayer K, Patel P, Rabkin C, Thorne J, Brooks J, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Rate and Risk of Transmissible HIV RNA (≥ 1500 copies/mL) Among Adults on ART,” CROI 2018, Boston MA (Accepted Oral)
144. Poteat T, Hanna D, Rebeiro P, Klein M, Silverberg M, Eron J, **Horberg M**, Kitahata M, Mathews W, Mattocks, Mayor A, Rich A, Moore R, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Characterizing the HIV Continuum of Care for Transgender Women in North America,” CROI 2018, Boston MA
145. **Horberg M**, Blank J, Rubenstein K, Hurley L, Kadlecik P, Klein D, Silverberg M, “Beyond Viral Suppression: Broadening Quality Measures (QM) for Total HIV Patient Care,” Abstract 633, CROI 2018, Boston MA
146. Rebeiro PP, Gange S, Althoff K, Berry S, **Horberg M**, Rachlis B, Yehia B, Moore R, Sterling T, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), “Impact of Medicaid Expansion under the Affordable Care Act (“Obamacare”) on HIV Viral Suppression Outcomes in the United States, 2008-2015,” 22nd International Workshop on HIV and Hepatitis Observational Databases (IWHOD), 2018, Fuengirola, Spain
147. Powers-Happ, Monroe A, Young H, Ma Y, Greenberg A, Benator D, **Horberg M**, Castel A, on behalf of the DC Cohort Executive Committee, Abstract 342, “The Impact of Glycemic Control on CD4 Cell Count in Persons Living with HIV and Diabetes Mellitus—Washington, DC,” IDSA 2019, Washington, DC
148. Jaurretche M, Byrne M, Powers-Happ L, Levy M, **Horberg M**, Castel A, Monroe A, on behalf of the DC Cohort Executive Committee, Abstract 1320, “HIV Care Continuum Outcomes among Newly Diagnosed PLWY in Washington, DC,” IDSA 2019, Washington, DC
149. Monroe A, Levy M, Greenberg A, Moore R, Keruly J, **Horberg M**, Mohanraj BS, Kumar P, Castel A, on behalf of the DC Cohort Executive Committee, Abstract 2492, “Differences between Individuals Currently Taking Integrase Inhibitor (INSTI)-Based Therapy and Those Not Taking INSTIs in the Era of INSTIs as Recommended First-Line Therapy,” IDSA 2019, Washington, DC
150. Silverberg MJ, Sarovar V, Satre D, Alexeeff S, Leyden W, Lam J, Anderson A, Hechter R, Hu H, Marcus J, Towner W, Yuan Q, **Horberg M**, “Excess Mortality in Persons with HIV After Cancer Diagnosis,” CROI 2020, Boston MA
151. Lam J, Leyden W, Reynolds K, **Horberg M**, Towner W, Hechter R, Vupputuri S, Leong T, Avula H, Harrison T, Lee K, Sung S, Neugebauer R, Go A, Silverberg M, “HIV Severity and Incident Heart Failure among Patients in a Large Healthcare System,” CROI 2020, Boston MA

152. Marcus J, Leyden W, Anderson A, Hechter R, **Horberg M**, Hu H, Lam J, Towner W, Yuan Q, Silverberg MJ, "Increased Overall Life Expectancy but Not Comorbidity-Free Years for People with HIV," CROI 2020, Boston, MA
153. **Horberg M**, Leyden W, Hechter R, Lam J, Hu H, Anderson A, Marcus J, Yuan Q, Go A, Towner W, Silverberg MJ, "Modifiable Risk Factors and Incident CKD and CVD among HIV+ and HIV- Patients," CROI 2020, Boston MA
154. Lesko C, Edwards J, Jing Y, Moore R, **Horberg M**, Rebeiro R, Rich A, Silverberg MJ, Mayor A, Eron J, Crane H, Mathews WC, Althoff K, Poteat T, "Progression through the HIV Care Continuum for Transgender Women in the NA-ACCORD," CROI 2020, Boston MA
155. Oliver C, Lau B, Althoff K, Buchacz K, Crane H, Gill MJ, **Horberg M**, Mayer K, Mayor A, Moore R, Schranz A, Sterling T, Pettit A, Rebeiro P, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Mental Health and Substance Use Services and Retention in HIV Care in North America," CROI 2020, Boston MA
156. Althoff K, Brown T, Burkholder G, Crane H, Delaney J, Elion R, Galaviz K, Gange S, **Horberg M**, Palella F, Silverberg MJ, Tate J, Moore R, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Myocardial Infarction by Atherosclerotic Cardiovascular Disease (ASCVD) Risk Score," CROI 2020, Boston MA
157. Rebeiro P, Jenkins C, Bian A, Lake J, Bourgi K, Althoff K, Floris-Moore M, **Horberg M**, Tate J, Willig A, Moore R, Gange S, Sterling T, Koethe J, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Diabetes, Weight Gain, and Integrase Inhibitor Use in North American HIV+ Persons," CROI 2020, Boston MA
158. Davy-Mendez T, Napravnik S, Gebo K, Althoff K, Gill MJ, **Horberg M**, Mathews WC, Eron J, Martin J, Lau B, Buchacz K, Lima V, Klein M, Berry S, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "Cause-Specific Hospitalization Trends among North American Persons with HIV 2005-2015," CROI 2020, Boston MA
159. Lee J, Lau B, Eron J, Bosch R, Kitahata M, Fleming J, Gill MJ, Mathews WC, Sterling T, Lima V, Silverberg MJ, **Horberg M**, Althoff K, Moore R, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), "High Probability of Survival in Patients Who Maintain Viral Loads <200 Copies/mL," CROI 2020, Boston MA
160. Akselrod H, Byrne M, Monroe A, Levy M, Denyer R, Klein A, **Horberg M**, Castel A, Doshi R, Secco A, Lucar J, Squires L, Schroeter S, Benator D, for the DC Cohort Executive Committee, "Geographic estimation of Sexual HIV Transmission Burden in the Era of U=U; Data from the DC Cohort," CROI 2020, Boston MA
161. Levy M, Monroe A, **Horberg M**, Benator D, Castel A, for the DC Cohort Executive Committee, "Cardiovascular Risk Factors among Persons with Spontaneous Control of HIV Replication," CROI 2020, Boston MA
162. Powers-Happ L, Monroe A, Young H, Ma Y, Greenberg A, **Horberg M**, Castel A, "Influence of HbA1C Trends on Diabetes Complications among PLWH with Diabetes," CROI 2020, Boston MA
163. Byrne M, Monroe A, Powers-Happ L, Doshi R, **Horberg M**, Castel A, "Substance Use and Engagement in Care: A Latent Class Analysis of PLWH in DC Cohort," CROI 2020, Boston MA
164. Kasale P, Stewart C, Humes E, Zhang J, Rebeiro P, **Horberg M**, Rich A, Silverberg M, Hyle E, Althoff K, "Age at ART Initiation in the "Treat All" Era: Results from the PEARL Model," IWHOD 2020, Sitges, Spain

165. Lee J, Humes E, Lau B, McKaig R, Palella F, Klein M, Fleming J, Rebeiro P, Eaton E, Crane H, Mathews C, **Horberg M**, Silverberg M, Moore R, Althoff K, for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, “Cumulative Incidence of Virologic Nonsuppression following Initial Suppression: Complete Case Analysis vs. Imputation for Left-Censored HIV RNA Measurements,” IWHOD 2020, Sitges, Spain
166. Park L, McGinnis K, **Horberg M**, Jefferson C, Bastarche L, Gangireddy S, Silverberg M, Leyden W, Napravnik S, Agil D, Abraham A, D’Souza A, Althoff K, on behalf of the CIVET collaboration of the NA-ACCORD of IeDEA, “SARS-CoV-2 Testing and Positivity among Persons with & without HIV in 6 US Cohorts,” CROI 2021, Chicago, IL (Accepted)
167. Klein M, Young J, Althoff K, Cahay E, Franco R, Gill MJ, **Horberg M**, Hull M, Kim N, LoRe V, Moore R, Price J, Sebastiani G, Silverberg M, “Are Modern Antiretrovirals Hepatotoxic? Signals in Patients Starting ART in NA-ACCORD,” CROI 2021, Chicago, IL (Accepted)
168. McGinnis K, Justice A, Moore R, Silverberg M, Althoff K, Karris M, Lima V, Crane H, **Horberg M**, Klein M, Gange S, Gebo K, Mayor A, Tate J, “Calibration of the VACS Index 2.0 for Estimating Mortality among PWH in North America,” CROI 2021, Chicago, IL (Accepted)
169. Kim HN, Nance R, Whitney B, Althoff K, Moore R, Silverberg M, **Horberg M**, Mayor A, Cacay E, Hull M, Lo Re V, Klein M, Delaney J, Kitahata M, “Prediction Model for End-Stage Liver Disease among People with HIV in the NA-ACCORD,” CROI 2021, Chicago, IL (Accepted)
170. Kim HN, Newcomb C, Carbonari D, Cachay E, Gill MJ, Hull M, Kostman J, Lim J, Silverberg M, **Horberg M**, Mayor A, Kitahata M, Klein M, Lo Re V, “Hepatocellular Carcinoma and HBV Viremia in HIV/HBV-Coinfected Persons in NA-ACCORD,” CROI 2021, Chicago, IL (Accepted)
171. Coelho L, Jenkins C, Shepherd B, Pape J, Mejia F, Padgett D, Crabtree-Ramirez B, Grinsztejn B, Althoff K, Joethe J, Marconi V, Tien P, Willig A, McGowan C, Rebeiro P, **Horberg M**, “Weight gain Post-ART in HIV+ Latinos/AS Differs in the US, Canada, and Latin America,” CROI 2021, Chicago, IL (Accepted)
172. Li J, Humes E, Hanna D, Lee J, Althoff K, Moore R, Crane H, Colasanti J, **Horberg M**, Nijhawan A, D’Souza G, Rentsch C, Gebo K, Buchacz K, “Disparities in Timely Receipt of ART Prescription in HIV Care in the U.S., 2012-2018,” CROI 2021, Chicago, IL (Accepted)
173. Moeng L, Byrne M, Monroe A, Maillipedi V, , **Horberg M**, Castel A, Wilcox R, “The Association of Low Nadir CD4/CD8 with CVD and NADC in the DC Cohort,” CROI 2021, Chicago, IL (Accepted)
174. Silverberg M, Levine-Hall T, Anderson A, Alexeeff S, Lam J, Hare B, Williams A, Cavassini M, **Horberg M**, “Prevention of Cardiovascular Disease in Persons with and without HIV,” CROI 2021, Chicago, IL (Accepted)
175. Lam J, Gilsanz P, Lee C, Hou C, Leyden W, Satre D, Flamm J, Towner W, **Horberg M**, Silverberg M, “Dementia Incidence among ART-Treated People with HIV in a Primary Care Setting,” CROI 2021, Chicago, IL (Accepted)
176. Humes E, Lee J, Li J, Hanna D, Marconi V, Colasanti J, Crane H, Kitahata M, Bosch R, Shah S, **Horberg M**, Silverberg M, Althoff K, Moore R, Buchacz K, “Trends and Disparities in Achieving Viral Suppression in the United States, 2012-2018,” CROI 2021, Chicago, IL (Accepted)
177. Silverberg M, Levine-Hall T, Lea A, Leibowitz A, **Horberg M**, Hare CB, Luu M, Flamm J, Satre D, “Changes in Substance Use, Depression and Anxiety after Implementaiton of Self-Administered Screening and Follow-Up Treatment in HIV Primary Care Settings,” Addiction Health Services Research Conference 2021, Boston, MA (Accepted)

Abstracts and Oral Presentations Pending Presentation or Awaiting Disposition

1. Watson E, **Horberg M**, Jefferson C, Certa J, Althoff K, Williams C, Moore R, “Clinical Conditions Associated with PASC in Kaiser Permanente Mid-Atlantic States,” CROI 2022, Denver, CO (Submitted)
2. **Horberg M**, Watson E, Jefferson C, Certa J, Althoff K, Williams C, Moore R, Post-Acute Sequelae of SARS-CoV-2: Clinical Condition Comparison in a Matched Cohort,” CROI 2022, Denver, CO (Submitted)
3. Miller M, Certa J, Eberhart L, Jefferson C, **Horberg M**, “Medication Adherence During COVID-19 in Patients with HIV and Comorbid Conditions,” CROI 2022, Denver, CO (Submitted)
4. Thorne J, Hanna D, Parcesepe A, Althoff K, Colasanti J, Crane H, French A, Gange S, Gebo K, Hessel N, **Horberg M**, Moore R, Silverberg M, Rebeiro P, the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA, “Effect of AIDS Drug Assistance Program Variability on Timely ART & Viral Suppression,” CROI 2022, Denver, CO (Submitted)
5. Lang R, Althoff K, Closson K, Gerelotti D, **Horberg M**, “Prevalence of Mental Health Disorders and the Effects on the HIV Care Continuum,” CROI 2022, Denver, CO (Submitted)
6. Lang R, Gill MJ, Moore R, Silverberg M, Willig A, Mayor A, Loutfy M, Klein M, Justice A, **Horberg M**, “Prevalence of Anemia and Risk Factors in People with HIV in the Modern ART Era,” CROI 2022, Denver, CO (Submitted)
7. Barth S, Castel A, Monroe A, Xiao J, **Horberg M**, “High Incidence of COVID-19 Infection and Related Stigma among a Cohort of PWH in DC,” CROI 2022, Denver, CO (Submitted)
8. Castel A, Monroe A, **Horberg M**, Greenberg A, “COVID-19 Related Disruptions in the HIV Care Continuum in a Large Urban Cohort of PWH,” CROI 2022, Denver, CO (Submitted)
9. Certa J, Jefferson C, Watson E, **Horberg M**, Silverberg M, Napravnik S, Browne L, “Differences in COVID-19 Testing, Positivity, and Outcomes by Race, Sex, and Health System Setting in a Large Diverse US Cohort,” National Big Data Health Science Conference 2022, Charleston, SC (Submitted)
10. Althoff K, Silverberg M, **Horberg M**, Gordon K, Justice A, Gebo K, Certa J, Park L, McGinnia K, Freeman A, Agil D, Williams C, “Impact of Discontinuity in EHR Data Pipelines on Inferences that are Contingent upon SARS-CoV-2 Testing or Vaccination Data: Lessons Learned from the CIVETS Collaboration of 5 Healthcare Systems,” National Big Data Health Science Conference 2022, Charleston, SC (Submitted)

PRESENTATIONS AND GRAND ROUNDS (selected)

1. “*Updated Recommendations for Primary Care for People with HIV*,” IDWeek, October 24, 2020, Washington DC
2. “*Sexual Health for Men who have Sex with Men*,” November 13, 2020, Kaiser Permanente Mid-Atlantic States, Washington, DC.
3. “*Transgender Health Care*,” November 5, 2020, Kaiser Permanente Mid-Atlantic States, Rockville, MD
4. “*Providing Culturally Competent Care to LGBTQ Populations in a Large Healthcare System*,” September 20, 2020, CDC STD Prevention Conference, Atlanta, GA
5. “*Kaiser Permanente Mid-Atlantic States’ Hepatitis Program*,” April 27, 2017; Centers for Disease Control and Prevention, Atlanta, GA

6. *"KP HIV Experience"*, MAPMG HIV CME, May 6, 2017; Kaiser Permanente Mid-Atlantic States, Rockville, MD
7. *"Kaiser Permanente Mid-Atlantic States' Hepatitis C (KPMAS HCV) Program,"* June 18, 2014; Centers for Disease Control and Prevention, Atlanta, GA
8. *"Evaluating Effectiveness of HIV Care in Light of the Affordable Care Act (ACA)"*, November 26, 2013; Children's National Medical Center, Washington, DC
9. *"Evaluating Effectiveness of HIV Care in Light of the Affordable Care Act (ACA)"*, November 1, 2013; Vanderbilt University, Nashville, TN
10. *"What's Hot in HIV Clinical Research,"* IDWeek 2013 (43rd Annual Meeting of the Infectious Disease Society of America), October 2, 2013, San Francisco, CA
11. *"The Access to Care Committee Update,"* PACHA Public Forum at XIX International AIDS Conference, July 25, 2012, Washington, DC
12. *"Prioritizing HIV Care in the United States,"* Expert Session at XIX International AIDS Conference, July, 2012, Washington, DC
13. *"HIV Research in KP/GHC and the HMORN,"* HMO Research Network Annual Meeting, Seattle, Washington, May 1, 2012
14. *White House LGBT Conference on HIV/AIDS*, panel member, Atlanta, Georgia, April 19, 2012
15. *"HIV Care, Quality Metrics and Quality Outcomes: Kaiser Permanente and the HIV Challenge,"* Centers for Disease Control and Prevention HIV Division (invited presentation), Atlanta Georgia, April 11, 2012
16. *"HIV Care in Kaiser Permanente and the HIV Challenge,"* Presentation to the US Congressional HIV Caucus, Washington, DC, March 2, 2012
17. *"Making Chlamydia Screening a Priority in Medical Groups: Lessons Learned from HIV ,"* National Chlamydia Coalition Conference, Washington DC, January, 2012
18. *"Introduction to KP HIV Challenge,"* Center for Medicare and Medicaid Innovations Summit, Washington DC, January, 2012
19. *"HIV Care in Kaiser Permanente and the KP HIV Challenge,"* American Health Insurance Plans, February, 2012
20. *"HIV Research in Kaiser Permanente"*, NIH HIV Research Rounds, Bethesda, MD, September, 2011
21. *"Laboratory Monitoring for HIV+ Patients: What You Need to Know,"* 49th Annual Meeting of the Infectious Diseases Society of America, Boston, MA, October, 2011
22. *"The Development and Implementation of HIV Quality Measures and Implications for Care,"* Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, September, 2011
23. *"The Development and Implementation of HIV Quality Measures and Implications for Care,"* New York University Medical School, New York, NY, October, 2011
24. *"Optimized Multidisciplinary Care Teams Enhance Antiretroviral Therapy Adherence—What We Know,"* 6th International AIDS Society Satellite Symposium, Rome, Italy, July, 2011

25. "Addressing Upstream Determinants of Treatment Access, Adherence, & Outcomes: Care Team Composition," 6th International Conference on HIV Treatment and Prevention Adherence, Miami, FL, May, 2011
26. "HIV in the US in 2011...and Beyond," American College of Physicians Annual Meeting, San Diego, CA, April, 2011
27. "HIV Care in KP in 2011...and Beyond," 7th KP HIV, Hepatitis, and STI Conference, April, 2011
28. "Development of National and Multiagency HIV Care Quality Measures," Committee to Review Data Systems for Monitoring HIV Care, Institute of Medicine of the National Academies, February, 2011
29. "Proposed and Continuing Metrics—NCQA and HEDIS," 2010 HIV National Summit on Diagnosis, Prevention, and Access to Care, Washington, DC, November, 2010
30. *Physician Issues in HIV Quality Measures*, Infectious Disease Society of America Annual Meeting, Vancouver, Canada, October 24, 2010
31. *HIV in the US and KP in 2010 and Beyond*, The Permanente Medical Group Division of Research Seminar, September 7, 2010
32. *HIV Quality Measures: National Development and in Kaiser Permanente*, American Medical Association-Physician Consortium for Performance Improvement, August 30, 2010
33. *Access to HIV Care and Private Insurance: Payment for Treatment—Kaiser Permanente*, National Academies Institute of Medicine Workshop on HIV Access to Care, Washington, DC, June 21-22, 2010
34. *KP HIV Program*, Presentation to Kaiser Foundation Health Plan National Leadership Team, Oakland California, June, 2010
35. *HIV in the US in 2010 and Beyond—Where We're Going*, American Conference on the Treatment of HIV, Denver Colorado, May, 2010 (opening plenary)
36. *Barriers and Facilitations to HIV Testing in Private Care Settings*, National Academies Institute of Medicine Workshop on HIV Testing, Washington, DC, April 15-16, 2010
37. *HIV Quality Measures as Part of National HIV/AIDS Strategy*, National HIV/AIDS Strategy Consultation, December 2009
38. *HIV Quality Measurement Through Electronic Health Records*, NCQA Policy Conference, December, 2009
39. *HIV in the World, US, and KP*, NABC Conference, July, 2009
40. Roundtable co-Chair, *Metrics and Evaluation Measures for Monitoring the Implementation of Routine HIV Testing*, April, 2009—final report available at http://www.hivforum.org/storage/hivforum/documents/metrics/hiv_testing_metrics_report_12.14.09.pdf
41. HIV Testing in Managed Care or Large Health Systems, *Metrics and Evaluation Measures for Monitoring the Implementation of Routine HIV Testing*, April, 2009
42. Quality Measurement in HIV and Recommendations for Improvement, 6th National HIV/AIDS, Hepatitis, and STD Conference, April, 2009

43. What We Know and What We Don't Know about the Effectiveness of Implementing Routine HIV Testing: The Private Sector Perspective, *2008 National Summit on HIV Diagnosis, Prevention, and Access to Care*, November, 2008
44. Investigating HIV Quality Performance and Outcomes in Kaiser Permanente, Kaiser Permanente Northern California Division of Research, January, 2008
45. Clinical Trials in Managed Care Settings, Forum for Collaborative HIV Research, January, 2008
46. HIV Testing in Kaiser Permanente, Kaiser Permanente National Diversity Conference, November, 2007
47. HIV Antibody Testing, Kaiser Permanente Northern California Laboratories, September, 2007
48. Components of Care, KP National HIV, Hepatitis, and STD Conference, April, 2007
49. HIV 101 and HIV in KP, Center for Health Research, April, 2007
50. Expanded Access in Kaiser Permanente, Forum for Collaborative HIV Research, February, 2007
51. HIV Antibody Testing in Kaiser Permanente and Group Health Cooperative, *Opportunities for Improving HIV Diagnosis, Prevention, and Access to Care in the U.S.*, November, 2006
52. "HIV at 25: The KP Experience," Kaiser Permanente National Diversity Conference, October, 2006
53. LGBT Health Challenges, KP National Diversity Conference, November, 2000
54. Panel Discussion, Harvard University and AAHP, June, 1997—Physicians, Managed Care, and the Media
55. "Primary Care of the LGBT Patient", Kaiser Santa Clara, June, 2002
56. HIV Care, KP national nursing update teleconference, 2000 and 2002
57. ABC's of AIDS to Cupertino Union School District, January 1999

CURRENT RESEARCH: M. HORBERG, MD, AS PRINCIPAL OR SITE INVESTIGATOR

ACTIVE

R01HL132640 Silverberg (PI) 12/15/2016-11/30/2021

National Heart, Lung, and Blood Institute

HIV Status and Incidence and Outcomes of Heart Failure

The overall purpose of this study is to work with our clinical and policy leaders in HIV and CHF care to quantify the risk of congestive heart failure (CHF) among HIV-infected patients, which antiretroviral therapy medications have increased risk for CHF and which may be protective, as well as develop care patterns for CHF among our HIV-infected patients.

Role: Co-Investigator

R24AI152598 Castel (PI) 06/01/20-05/31/2025

National Institute of Allergy and Infectious Disease

The George Washington University

The DC Cohort: A Longitudinal Population-Based Cohort Study of People Living With HIV in Washington, DC

The goals of this study are 1) enhance the Cohort database to incorporate new data sources to comprehensively describe and monitor HIV and co-occurring conditions; 2) expand the use of the existing DC Cohort Clinical Dashboard to monitor HIV care outcomes as well as key indicators related to ending the HIV

epidemic; and 3) use the Cohort as a platform from which to develop pioneering interventions to improve the quality of care of PLWH.

Role: Co-Investigator

Kaiser Permanente Research Bank Horberg (PI)

01/01/2014-12/31/2022

Kaiser Permanente Research Bank

In this study, KP Research Bank aims to recruit 280K members total across all KP regions to increase the overall Research Bank collection to 500K. Members will be consented to provide a biospecimen and complete a survey. This region will participate in the recruitment and other Research Bank-related efforts, including scientific, strategic and operational.

Role: Principal Investigator

5U01AI069918-02

Moore (PI)

09/01/2008-06/30/2021

National Institute of Allergy and Infectious Diseases

North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD)

This is the North America response to IeDEA, and for which KP Northern California and Mid-Atlantic States participates. It is a collaborative cohort compendium and analysis for purposes of achieving sufficient power to address issues that could not be adequately addressed by single cohorts.

Role: Site Principal Investigator

5U01AI069918-S1

Moore (PI)

05/01/2019-06/30/21

National Institute of Allergy and Infectious Diseases

CIVETS of the North American AIDS Cohorts Collaboration on Research and Design (NA-ACCORD)

The purpose of this study is for the existing NA-ACCORD collaborators to share data collection instruments, algorithms for identifying COVID-19 disease, and analytic approaches to expedite answers to urgent questions in multiple data sources.

Role: Co-Investigator

Care Management Institute Horberg (PI)

01/15/2007-12/31/2020

Kaiser Permanente HIV Quality Improvement and Performance Program

We seek to determine quantitative measures of HIV care and outcomes in Kaiser Permanente, which has never been done on a systematic basis in a managed care organization previously. We seek to then initiate quality improvement programs where we determine there are opportunities for improvement.

Role: Principal Investigator

5U01AA026230

Silverberg (PI)

9/11/2017-7/31/2021

National Institute on Alcohol, Abuse and Alcoholism

Implementing Computerized Substance Use and Depression Screening and Evidence-Based Treatments in an HIV Primary Care Population

The purpose of the overall study is to address the important topic of alcohol, smoking and other substance use and comorbidity screening and treatment among HIV-impacted patients. This study represents an important next step in the evolution of our top-quality HIV care in the context of an aging HIV patient population and has important implications beyond the Kaiser Permanente system.

Role: Site Principal Investigator

IN-UN-236-4291

Silverberg, Horberg (co-PI)

12/15/2017-3/31/2021

Gilead, Inc.

HIV Infection, Use of Tenofovir and Other Antiretrovirals, and Risk of Fatal and Non-Fatal Comorbidities: Cohort study in Kaiser Permanente

The purpose of the overall study is to primarily compare the incidence rate of fatal and non-fatal comorbidities in HIV patients with incidence rates among matched HIV-uninfected controls, and HIV-uninfected individuals prescribed PrEP.

Role: Multiple Principal Investigator

5U01AA026230

Silverberg (PI)

09/15/2017-08/31/2020

National Institute of Health

COMpAAAS Tripartite: ART-CC, KP, and VA

The purpose of the overall study is to participate in a scientific collaboration across three grant partners to assemble data sets, including electronic health record data. Partners will interpret and disseminate results of the study through conference abstracts and manuscripts.

Role: Site Principal Investigator

5756

Newman-Toker (PI)

05/01/18 – 12/31/2020

Gordon & Betty Moore Foundation

National Diagnostic Performance Dashboard to Measure and Track Diagnostic Error Using Big Data.

The goal of this study is to measure and track “missed diagnoses” of sepsis, stroke, and myocardial infarction and display information in ways that can be acted upon to reduce morbidity and mortality.

Role: Co-Investigator

COMPLETED/INACTIVE

1R01HL120894-01 (Gold)

05/15/2014-11/30/2019

National Heart, Lung, and Blood Institute

SPREAD NET: Practices Enabling Adapting and Disseminating in the Safety NET

This is a study with Dr. Horberg (KPMAS) as site PI with Dr. Rachel Gold (Kaiser Permanente North West) as overall PI. Dr. Horberg’s role in this study is to mentor Dr. Gold on the study design and execution, as well as help derive and evaluate the performance metrics to be used in the study.

Role: Site Principal Investigator

5UM1AI069503 (Castel)

12/01/2016-11/30/2020

National Institute on Drug Abuse

The George Washington University

Terry Beirn CPCRA Clinical Trials Unit: A City-wide DC Cohort of HIV Infected Persons in Care in the District of Columbia

The overall purpose of this study is to establish a clinic-based city-wide longitudinal cohort that will describe clinical outcomes in outpatients with HIV/AIDS receiving care in Washington, DC, with the goal of improving HIV/AIDS care in DC.

Role: Site Principal Investigator

PCORI—PCORnet--RNG209223

04/8/2014-04/05/2019

Patient-Centered Outcomes Research Institute (McGlynn)

KP & Strategic Partners Patient Outcomes Research to Advance Learning (PORTAL) Network

In this project, this region will collaborate with patients, clinicians, and operational leaders to develop the infrastructure necessary to create a highly functioning clinical data research network (CDRN).

Role: Site Principal Investigator

R01 DA031059-01A1 (Linas)

06/15/2013-05/31/2017

National Institute on Drug Abuse

Simulation Modeling to Improve HIV/HCV Screening, Treatment & Care

The overall purpose of this study is for multi-institution, collaborative effort to construct a simulation model of HIV/HCV co-infection that includes HCV screening, linkage to care, loss to follow-up, and treatment for HIV and HCV.

Role: Co-Investigator

National Institutes of Mental Health

08/01/09-12/31/12

Optimizing Multidisciplinary HIV Care Team for Maximal HAART Adherence (1R21MH085553-01A1)

Retrospective cohort study to determine optimized HIV multidisciplinary care team to maximize HAART adherence and other HIV outcomes and minimize urgent care utilization

141-9127

01/15/04-12/31/07

NIAID Bridge Award

Michael A. Horberg, MD MAS—Signature on File

Page 43

11/1/2021

Epidemiology & Clinical Outcome of HIV/HCV Co-Infection

This is a Kaiser Permanente program-wide analysis of an HIV+/HCV+ cohort, including testing rates, compared to the VA's program wide cohort and treatment rates of HIV+/HCV+ patients.

KPNC Community Benefits Research Fund

01/1/10-12/31/12

Impact of Missed Office Visits on HIV Outcomes and Mortality

A retrospective cohort study investigating the impact of missed office in the first twelve months after HIV diagnosis on later mortality, treatment adherence, and other HIV-related health outcomes. Comparisons will be made to the previously published work at University of Alabama, Birmingham.

Merck Laboratories

08/01/08-12/31/12

Considerations of Emerging Issues in the Treatment of HIV (“CEITH”)

Retrospective cohort study investigating issues of low level viremia in patients on antiretroviral therapy, advanced treatment failure in HIV-infected patients, and uptake of a new antiretroviral drug class in a closed healthcare system.

115-9837

01/1/07-12/31/10

KPNC Community Benefits

Differences in Syphilis Incidence, Disease, and Treatment in KPNC HIV Infected and HIV uninfected Populations

An epidemiologic analysis of syphilis disease among HIV-infected compared to HIV-uninfected patients since 1995 in KPNC. Disease stage, response to therapy, and recurrence of syphilis disease is considered.

115-9410

01/1/07-12/01/10

Gilead Sciences

Treatment Regimen, Provider, and Clinical Characteristics Associated with Receipt of HAART: An Analysis from Kaiser Permanente

The goal of this retrospective cohort study using data from KPNC, KPNW, KPGA is to determine the predictors of initiating HAART therapy in the modern treatment era and has that changed over time.

115-9058

09/12/06-09/11/11

Abbott Laboratories

Economic Implications of Care of HIV-Positive Patients with Multi-Drug Resistance within a Managed Care Population (MDR)

This retrospective study using cost and other data is to determine the added overall cost of patients who are on their third (or likely greater) HAART regimen compared to antiretroviral naive patients beginning their first regimen in the modern HIV treatment era.

115-9856

10/16/06-12/31/10

Gilead Sciences

Effect of Tenofovir on Renal Function--An Observational Cohort Study

We will determine the incidence of change in renal function of patients taking TDF and compare that to patients on other NRTI. We will also attempt to determine if TDF preparation makes a difference (Viread vs. Truvada).

NIH (AHRQ R01)

01/01/10-12/31/16

Preventive Health Index for HIV-Infected Population

Retrospective study to assess the impact of preventive health services on the ongoing and long term care of HIV-infected patients in KP. This work will extend the original work on the preventive health index by Tom Vogt, PhD. Data from KPNC, KPSC, KPNW, and KPGA will be utilized. Dr. Horberg is KPNC PI.

NIH (NIAID R01)

07/01/12-06/31/16

HIV and HCV Co-Infection and Care Implications

This is a newly funded study with Dr. Horberg (KPMA) as site PI with Dr. Benjamin Linas (Boston University) as overall PI. We will be exploring using retrospective data (which KPMA will contribute) the cost and effectiveness implications of care for these patients—the HCV mono-infected and the HIV/HCV co-infected.

PENDING

None.

OVERLAP

None.